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ABTRACT 
Introduction 
Diabetes is considered a major threat to human health in both developed and developing 
nations. Cardiovascular disease which is common in diabetic patients has increased the 
overall disease affliction. Moreover, stress-induced hyperglycemia has led to increased 
mortality and morbidity in patients with an acute myocardial infarction (MI), whether the 
patient has diabetes or not. In addition, acute MI might stem from stress-induced 
hyperglycemia capability to increase inflammation and oxidative stress resulting in a worse 
functional cardiac outcome. Hyperglycemia-induced oxidative stress can similarly result in 
the formation of miss folded or damaged proteins that may be eliminated by the ubiquitin-
proteasome system (UPS).  
Futhermore, hyperglycemia-induced oxidative stress can also result in dysregulation of the 
UPS that removes these misfolded proteins. Additionally, an increasing body of evidence 
implicates UPS dysfunction in cardiac diseases and hyperglycemia which has been associated 
with increased inflammation and blunted cardiac function in response to ischemia-
reperfusion. Literature however is blurred whether a reduction or a rise in the UPS is 
damaging with hyperglycemia and in response to ischemia-reperfusion. In light of this, we 
hypothesized that UPS inhibitors such as Z-Leu-Leu-Leu-al (MG-132) and lactacystin, 
protects the rat heart against ischemia-reperfusion under hyperglycemic perfusion conditions. 
Materials and Methods 
Isolated rat hearts were perfused ex vivo with Krebs-Henseleit buffer containing 33 mM 
glucose vs. controls (11 mM glucose) for 60 min, followed by 20 min global ischemia and 60 
minutes reperfusion ± PI treatment (MG-132 and lactacystin), anti-inflammatory (Ibuprofen) 
and anti-oxidant (NAC). Infarct size was determined using Evans Blue dye and 1% 2,3,5-
triphenyl tetrazolium chloride (TTC) staining with 20 minutes regional ischemia and 2 hours 
reperfusion ± PI’s treatments. Tissues were collected at the end of the global ischemia 
experiments and analyzed for UPS activity, oxidative stress, apoptosis and inflammation. 
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Results 
Our data expressed a reduced cardiac contractile function in response to ischemia and 
reperfusion under hyperglycemic conditions as well as an increase in UPS activity. PI 
treatment resulted in cardio-protection for ex vivo rat heart model exposed to ischemia and 
reperfusion under hyperglycemic conditions as well as ibuprofen and NAC. In parallel 
lactacystin treatment significantly decreased myocardial oxidative stress, apoptosis, and 
inflammation which provided cardio-protection in response to ischemia and reperfusion 
under hyperglycemic conditions. 
Conclusions 
This study shows that acute hyperglycemia elicits myocardial oxidative stress, apoptosis and 
inflammation that in time results in an increase in contractile dysfunction following ischemia 
and reperfusion. However, we found that PI treatment with both MG-132 and lactacystin 
blunted high glucose-induced damaging effects which resulted in a robust cardio-protection 
in response to ischemia and reperfusion under hyperglycemic conditions, by reducing 
oxidative stress, decreasing apoptosis and limiting inflammation. A parallel outcome was 
observed at baseline although the underlying mechanisms driving this process still need to be 
clarified. Our findings indicate that the UPS may be a unique therapeutic target to treat 
ischemic heart disease in diabetic patients, and non-diabetic individuals that present with 
stress-induced hyperglycemia. In summary, this thesis established that PIs act as a novel 
cardio-protective intervention to treat acute hyperglycemia with associated cardiovascular 
complications. 
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Uittreksel 
Inleiding 
Diabeties word beskou as ‘n baie groot problem vir menslieke gesondhied vir biede die 
ontwikkel en onontwikkelende lande. Kardiovaskulêre siekte wat normaal met diabetiese 
pasiente geassoseerd word veroorsaak ‘n toeneemende druk, wat hierdie siekte laat toeneem. 
Verder meer vergroot stresgeïnduseerde hiperglukemie die mortaliteit van pasiente met of 
sonder diabeties wat akute miokardiale infarksie onder lede het. Akute miokardiale infarksie 
kan ook ontstaan van stresgeïnduseerde hiperglukemie se bekwaamheid om meer inflamasie 
en oksidante stress te veroorsaak wat in ‘n meer swakker funksionele kardiale toestand. 
Hiperglukemiegeïnduseerde oksidatiewe stres ook tot wanregulering van die ubikwitien-
proteosoomsisteem (UPS) wat wangevoude protïene verwyder, aanleiding gee. 
Kontrasterende data bestaan van verhoogde/verlaagde UPS aktiwietiet, sowel as met 
hiperglukemie en/of in reaksie tot isgemie-reperfussie. As gewolg hiervan,, hipotetiseer ons 
dat Z-Leu-Leu-Leu-al (MG-132) and lactacystin as ‘n nuwe kardiobeskermingsmiddel kan 
optree deur miokardiale oksidatiewe stress, inflamasie en UPS aktiwiteit te verlaag in reaksie 
op isgemie-reperfussie tydens akute hiperglukemiese toestande kan verlaag. 
Materiale en Metodes 
Geïsoleerde rotharte is ex vivo met Krebs-Henseleit buffer, wat, 33 mM glukose vs. kontrole 
(11 mM glukose) bevat, vir 60 min geperfuseer, daarna is dit deur 20 min globale isgemie 
gevolg en 60 min reperfussie ± PI behandeling (MG-132 and lactacystin), antiflammatoriese 
behandeling (Ibuprofen) en antioxidant behandeling (NAC). Infarkgrootte is bepaal deur 
Evans bou kleursel en 1% 2. 3-5 tripfeniel tetrazoloimcholierd (TTC) kleuring met 20 minute 
regionale ischemie, en 2 uur reprefussie ± PI’s behandeling. Weefsels is aan die einde van die 
globale isgemie eksperimente versamel, en vir oksidatewe stres, apoptose en inflammasie 
ontleed. 
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Resultate 
Ons data toon aan dat kardiale kontraktiele funksie in reaksie op isgemie-reperfussie onder 
hiperglukemiese toestande verlaag het asook ‘n toename in UPS aktiwitiet veroorsaak. PI 
behandeling het gelei tot kardiale beskerming vir ex vivo rotharte wat aan isgemie-reperfussie 
onder hiperglukemiese toestande blootgestel was sowel as ibuprofen en NAC. Parallel 
hiermee het lactacystin oksidatiewe stres, apoptose, inflmasie, en UPS aktiwiteit na isgemie-
reperfussie, verlaag in reaksie isgemie-reperfussie onder hiperglukemiese toestande. 
Gevolgtrekking 
Hierdie studie het bevind dat akute hiperglukemie, miokardiale oksidatiewe stres lei tot 
oksidante stress, apoptose, en inflamasie na kontraktiele wanfunksionering na isgemie-
reperfussie lei. Ons het bevind dat beide MG-132 en lactacystin behandeling, hoë glukose-
geïnduseerde skadelike effekte onderdruk, en kardiale-beskerming in reaksie op isgemie-
reperfussie onder hiperglukemiese toestande ondervind was deur oksidante stress, apoptose, 
en inflamasie te verlaag. ‘n Soorgelyke effek is tydens die basislyn waargeneem, alhoewel 
die onderliggende meganisme wat hierdie proses meer ondersoek instel. Ons bevinding dei 
dat die UPS ‘n nuwe behandeling teiken kan word in sgemie-geïnduseerde reperfussie onder 
aktute en chroniese hoë glukose toestande. In opsomming, het die tesis belowend bevindinge 
gevind wat ‘n nuwe terapeutiese intervensie vir die behandeling van akute hiperglukemie met 
geassosieërde kardiovaskulêre komplikasies gebruik kan word. 
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CHAPTER 1 
1.1 Background 
The dramatic increase in obesity and non-insulin-dependent diabetes mellitus (Type 2) 
during the past few decades has led to it being considered a major threat to human health 
in both developed and developing nations (Wild S et al., 2004; Bradshaw D et al., 
2007). Since cardiovascular complications and mortalities are common in diabetic 
patients (Mazzone T et al., 2008; Boudina S and Abel ED., 2007; Barr EL et al., 2007) 
this further increase the overall burden of the disease. It is therefore a necessity for a 
comprehensive understanding of the underlying biochemical and molecular mechanisms 
orchestrating the development of Type 2 diabetes and the onset of cardiovascular diseases 
(CVD). Various CVD are associated with diabetes such as coronary heart disease (CHD), 
myocardial infarction. Metabolic derangements play a fundamental role in the onset of 
diabetes and CVD. Here elevated metabolite availability, e.g. hyperglycemia, defined as 
an increase in glucose in the bloodstream, can cause oxidative stress that may contribute 
to the onset of diabetic cardiomyopathy (Ceriello A., 2000; Smart EJ and Li X-A, 
2007). Such metabolic abnormalities together with other subcellular defects and abnormal 
gene profiles may lead to cardiac cell death (Cai L et al., 2002) and by extension, 
contractile dysfunction. 
Diabetic patients have not benefitted as much from the progresses in the management of 
associated risk factors such as obesity, dyslipidemia, and hypertension that led to 
decreased mortality for non-diabetic individuals burdened with CHD (Kempler P., 
2005). The above-mentioned risk factors do not fully explain the excess risk for CHD 
associated with diabetes. CHD is caused due to a blockage or narrowing (stenosis) of the 
arteries that supply blood to the heart muscle, often due to a buildup of fatty plaque inside 
the arteries. A severe enough blockage can cause an ischemic event and if not treated 
promptly part of the heart muscle dies due to lack of oxygen also known as myocardial 
infarction (Boudina S and Abel ED., 2007; Barr EL et al., 2007). Therefore in recent 
years, much attention has been given to the association of mortality and morbidity risk 
and the incidence of hyperglycemia in patients admitted to intensive care units following 
acute myocardial infarction (MI), irrespective whether patients were  diabetic or not 
(Capes SE et al., 2003). Acute hyperglycemia has also been independently associated 
with impaired left ventricular function (Ishihara M et al., 2003) and a larger infarct size 
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due to an increased incidence of the no-reflow phenomenon (Iwakura K et al., 2003). A 
worse myocardial performance was also found in patients with acute MI and associated 
hyperglycemia (Poulsen SH et al., 2000). 
In an attempt to understand the mechanisms linking hyperglycemia to CVD there are 
several proposals how exactly such damage may occur. There is convincing evidence 
suggesting a key role for hyperglycemia-induced oxidative stress as a pivotal mechanism 
leading to myocardial cell death by increased endothelial cell apoptosis (Valgimigli M et 
al., 2003).  Furthermore, there is the suggestion that the damaging effects of stress 
hyperglycemia with an acute MI can stem from its ability to increase inflammation. Here 
amplified inflammatory reactions are linked to decreased cardiac function (Marfella R et 
al., 2003). Additionally, hyperglycemia-induced oxidative stress can result in the 
formation of excess misfolded or damaged proteins – usually eliminated by the ubiquitin-
proteasome system (UPS) – with detrimental consequences for cardiac function.  
1.2 Implication of the UPS 
An increasing body of evidence implicates UPS dysfunction in cardiac diseases and 
hyperglycemia. This has been associated with enhanced inflammation and blunted cardiac 
function in response to ischemia-reperfusion (I/R) (Evans JL et al., 2002; Palombella et 
al., 1994; Toth A et al., 2006,). The literature, however, is “blurred” whether a reduction 
or a rise in the UPS activity is damaging/protective with hyperglycemia and in response 
to I/R (Kuhn D et al., 2006; Marfella R et al., 2009; Powell SR et al., 2006; 
Tsukamoto O et al., 2010). An in-depth study on proteasome alterations in diabetic 
hearts has not been reported thus far, though greater proteasome functions were 
implicated as a damaging consequence in hearts exposed to high glucose levels 
(Mapanga RF et al., 2012). However, since increased reactive oxygen species (ROS) is 
associated with hyperglycemia within the context of both diabetes and myocardial 
ischemia, it is plausible that oxidative modification of proteasome subunits may alter 
proteasome function in this instance (Powell SR., 2006).  
The role of proteasome dysfunction within the context of diabetes and associated CVD 
remains to be determined as it remains uncertain whether an increased or decreased UPS 
is harmful with hyperglycemia and/or in response to I/R. For example, Pye et al. (2003) 
found that myocardial reperfusion injury is reduced by proteasomal inhibitors, while 
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others determined that UPS over-activity may augment the risk of complications during 
myocardial ischemia in diabetic patients (Marfella R et al., 2009). By contrast, others 
established that proteasomal deficiency may add to the detrimental effects of myocardial 
ischemia (Bulteau AL., 2001). Supplementary studies are consequently essential to 
determine the mechanisms underlying dysfunctional UPS in the heart under these 
conditions. In light of this, we hypothesized that proteasomal inhibitors (PI) (Lactacystin 
or Z-Leu-Leu-Leu-al [MG-132]) prevents the metabolic processes that occur during acute 
hyperglycemia with I/R; hence it is cardio-protective. Therefore, this thesis was designed 
to investigate the role of proteasome inhibition as a novel therapeutic intervention to help 
improve cardiac function following I/R under hyperglycemic conditions. The next section 
will look at the various forms and effects diabetes has on human physiology. 
1.3 The dire effects of diabetes mellitus 
Diabetes mellitus is one of the most common chronic diseases worldwide, and continues 
to rise in number and significance as changing lifestyles lead to reduced physical activity 
and increased obesity (World Health Organisation., 2006). This condition is 
characterized as a group of metabolic diseases where individuals display elevated glucose 
levels (Table1) either due to insufficient insulin secretion by the pancreas, or because 
cells do not respond to the insulin that is produced (Boussageon R et al., 2011). Classical 
symptoms of diabetes normally experienced are polyuria (frequent urination), polydipsia 
(increased thirst) and polyphagia (increased appetite) (Rother KI., 2007). Diabetes can 
be classified into four main categories: type 1, type 2, gestational diabetes, and secondary 
to other underlying disease or cause. 
Table 1.1 Interpretation of blood glucose levels 
Diabetic Care 27, Supp 1.1, 2004. 
Fasting Blood 
glucose 
2 hour after 75g glucose 
load 
Temporary diagnosis 
<5.6 mmol/l <7.8 mmol/l Normal 
5.6 – 7.0 mmol/l 7.6 – 11.0mmol/l IGT (“ Impaired Glucose 
Tolerance”) 
>7.0 mmol/l >11.1 mmol/l Diabetes 
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Type 1 diabetes mellitus is characterized by loss of the insulin-producing beta cells of the 
islets of Langerhans in the pancreas, thus leading to insulin deficiency. This type can be 
further classified as immune-mediated or idiopathic (Lambert P and Bingley PJ., 2007). 
The majority of type 1 diabetes is of the immune-mediated nature, where beta cell loss is 
due to a T-cell-mediated autoimmune attack. Type 2 diabetes mellitus (T2DM) is 
characterized by excessive hepatic glucose production, decreased insulin secretion, and 
insulin resistance. A number of lifestyle factors are known to play a significant role in the 
development of T2DM, including: obesity, lack of physical activity, poor diet, stress, and 
urbanization (Bugger H and Abel E., 2008). Gestational diabetes is well-defined as the 
first onset of diabetes mellitus in women during pregnancy caused by a surplus 
production of glucocorticoids (Lawrence JM et al., 2008). The fourth type of diabetes is 
a condition where hyperglycemia manifests with pancreatic or hormonal disease, or 
secondary to drug or chemical exposure, and also with certain genetic syndromes (Malik 
VS et al., 2010; National Diabetes Data Group, 1995). 
The rate of diabetes incidence has increased prominently over the last 50 years in parallel 
with obesity due to growing westernization of diets; jeopardizing the working class as 
indicated by increased T2DM prevalance (Epidemiology of Diabetes Interventions and 
Complications (EDIC) study., 2003). Recent data show that there are approximately 285 
million persons diagnosed with T2DM (compared to around 30 million in 1985), and that 
this number is expected to rise to 439 million by the year 2030 (Marcovecchio ML et al., 
2011). T2DM is typically a chronic disease that is associated with a shorter life 
expectancy (Fasanmade OA et al., 2008). This is partly due to a number of 
complications including: 2-4 times risk of CVD (already defined above), including 
ischemic heart disease and MI. Diabetes is also associated with long-term cardiovascular 
complications such as atherosclerosis (Fasanmade OA et al., 2008), thus further 
contributing to the overall burden of disease (Hayashi T et al., 2008). The prevalence, 
incidence, and mortality of CVD are unusually amplified in persons with diabetes 
compared with those without diabetes. In light of this, the current study focused on the 
role of acute hyperglycemia and its link to MI. The next section therefore discusses the 
substrate alterations that occur in both acute and chronic hyperglycemia. 
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1.4 Cardiac metabolism 
Chronic hyperglycemia that occurs with diabetes is mainly due to derangements in 
substrate metabolism which may impair cardiac function with I/R (Rahimi R et al.,  
2005) as well as long term complications. Acute hyperglycemia involving glucose levels 
that are extremely high is a medical emergency and can rapidly produce serious 
complications (such as fluid loss through osmotic diuresis). It is most often seen in 
persons who have uncontrolled insulin-dependent diabetes (Ceriello A., 2000; Smart EJ 
and Li X-A, 2007) and is independently associated with impaired left ventricular function 
(Ishihara M et al., 2003) as mentioned before. With diabetes, the heart uses fatty acids 
(FAs) more prominently resulting in both diastolic and systolic cardiac dysfunction (An 
D and Rodrigues B., 2006). We will thus next discuss cardiac energy metabolism of the 
normal adult mammalian heart for a better understanding of biochemical and molecular 
mechanisms involved in cardiac pathophysiology under hyperglycemic conditions.  
1.4.1 Substrate use of the heart under normal physiological conditions 
The heart has a high demand for provision of energy. The energy currency of the heart is 
adenosine triphosphate (ATP) and an entire pool of ATP is consumed 6-8 times per 
minute (Ashrafian H., 2011). To sustain this high energy demand a wide variety of 
energy sources are used such as carbohydrates, lactate, FAs, amino acids and ketones. 
Here FAs and carbohydrates constitute the major energy sources under normal 
physiological conditions. For a normal functioning heart, 70% of ATP assembly is 
generated by Fatty acid oxidation (FAO), whereas glucose and lactate accounts for the 
remainder (Gertz E.W et al., 1988; Neely J.R et al., 1972).  
1.5 Glucose uptake and metabolism 
Glucose is the major carbohydrate used by the heart and its uptake is dependent on the 
transmembrane glucose gradient and the content of the sarcolemmal glucose transporters 
1/4 (GLUT1/4). GLUT1 is more prominent at the sarcolemma and represents basal 
cardiac uptake (Kraegen EW et al., 1993) while GLUT4 is more dominant in the adult 
heart. Such transporters are usually located within an intracellular pool and translocate to 
the sarcolemmal membrane in a process mediated by insulin (Barnard RJ and 
Youngren JF., 1992; Fischer Y et al., 1997). However, GLUT-mediated glucose uptake 
can also be stimulated by insulin-independent mechanisms such as adenosine 
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monophosphate (AMP)-activated protein kinase (AMPK) which promotes GLUT4 
redistribution to the sarcolemmal membrane (Hausenloy DJ., 2012; Li J et al., 2004). 
Once inside, glucose is broken down into pyruvate through glycolysis.  
Phosphofructokinase-1 (PFK-1) is the rate limiting enzyme within the glycolytic pathway 
which catalyzes the production of fructose 1, 6-bisphosphate from fructose 6-phosphate 
(see Figure 1.1). PFK-1 is activated by fructose 2, 6-bisphosphate, which is formed from 
fructose 6-phosphate catalysed by PFK-2. Following glycolysis, the pyruvate generated is 
transported into mitochondria and decarboxylated to acetyl-CoA, a step mediated by the 
multi-enzyme complex pyruvate dehydrogenase (PDH) (Bowker-Kinley MM et al., 
1998; Holness M and Sugden M., 2003). PDH can be phosphorylated and inactivated by 
pyruvate dehydrogenase kinase (PDK). Acetyl-CoA then enters the Krebs cycle also 
known as the citrate acid cycle (CAC), which will be used throughout the rest of the 
thesis, where it is eventually broken down into water (H2O) and carbon dioxide (CO2) for 
ATP generation (Hausenloy DJ., 2012; Huang B et al., 2003) (Figure 1.1). As 
mentioned earlier, the heart also utilizes FAs; thus the next section will discuss its uptake 
and breakdown for energy production. 
 
 
 
 
 
 
Figure 1.1 Glucose uptake and oxidation under normal conditions. Insulin-mediated 
GLUT 4 translocation. GLUT 1 and 4 (glucose transporter 1 and 4); ATP (adenosine 
triphosphate, P (phosphate residue); PFK-1 (phosphofructokinase 1); PDH (pyruvate 
dehydrogenase); CAC (citric acid cycle).  Modified from An D and Rodrigues B., 2003 
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1.6 FA uptake and utilization 
As the heart has limited capacity to synthesize and store FA’s, it relies on a continuous 
exogenous supply. Circulating FAs are supplied to the heart via two sources, i.e. adipose 
tissue and triglyceride (TG)-rich lipoproteins (Augustus AS et al., 2006). This occurs 
through hydrolysis by lipoprotein lipase (LPL). FAs are then taken up into the 
cardiomyocyte by three transporters: cluster of differentiation 36 (CD36), FA transport 
protein (FATP), and FA binding protein plasma membrane (FABPPM) (Luiken JJ et al., 
1999; Ibrahimi A et al., 1999; Luiken JJ et al., 2002) (Figure 1.2). FAs are then 
converted to fatty acyl-CoA, which is transported into the mitochondrion through 
carnitine palmiyoyltransferase-1/2 (CPT-1/CPT-2). Inside the mitochondrion, fatty acyl-
CoA undergoes β-oxidation to generate acetyl-CoA, which is then further oxidized within 
the CAC. FA utilization can be regulated through various mechanisms such as activation 
of the transcriptional modulator, peroxisome proliferator-activated receptor-α (PPAR-α). 
When activated PPAR-α increases the expression of several enzymes involved in FA 
oxidation (Dressel U et al., 2003) (Figure 1.2). Malonyl-CoA is generated through 
carboxylation of acetyl-CoA [a reaction catalyzed by acetyl-CoA carboxylase (ACC)], 
inhibiting CPT-1 and FA oxidation. AMPK inhibits ACC which relieves its inhibition on 
CPT-1 and promotes FA oxidation. Similarly, malonyl-CoA decarboxylase (MCD) 
decreases malonyl-CoA by decarboxylating it to acetyl-CoA, thereby enhancing CPT-1 
and FA oxidation (Dyck JR et al., 1988; Dyck JR et al., 2004) (Figure 1.2).  
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Figure 1.2 Fatty acid uptake and oxidation under normal conditions. CD36 (cluster of 
differentiation 36); FATP (fatty acid transport protein); FABP (plasma membrane fatty 
acid binding protein);FA (fatty acid); TG (triglycerides); ACC (acetyl-CoA carboxylase); 
PPAR-α (Peroxisome proliferator-activated receptor-α); CPT-I (carnitine-palmitoyl 
transferase I); CACT (carnitine/acylcarnitine transferase). Modified from An D and 
Rodrigues B., 2003 
1.7 Interplay between glucose and FA  
The regulation of glucose and FA metabolism does not occur independently but rather a 
unique cross-talk exists between these substrates (Randle PJ et al., 1963; Saha AK et 
al., 1997). Here FAs impair basal and insulin-stimulated glucose uptake and oxidation (an 
event referred to as the Randle cycle) and impacts glucose utilization at numerous levels 
(Randle PJ et al., 1963) (Figure 1.3). Accumulation of FAs and augmented intracellular 
FA derivatives, such as fatty acyl CoA, diacylglycerol and ceramide impair insulin-
mediated glucose uptake through inhibition of insulin receptor substrates and protein 
kinase B (PKB) (Grundleger ML and Thenen SW., 1982; Itani SI et al., 2000 Stanley 
W et al., 2005). These FA metabolites trigger a serine kinase cascade, involving protein 
kinase C-θ and Ikβ kinase-β (interleukin kappa beta kinase-β) resulting in the serine 
phosphorylation of insulin receptor substrate (IRS) (Itani S.I et al., 2000). This in turn 
interferes with its ability to phosphorylate and activate phosphatidylinositol 3-kinase and 
PKB which decreases glucose uptake (Kim JK et al., 2004; Yuan M et al., 2001). 
Increased intracellular FA levels (as observered in diabetes) can stimulate PPAR-α and 
thereby promote the expression of FA oxidation genes, including pyruvate dehydrogenase 
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kinase-4 (PDK4), which is known to inhibit PDH and pyruvate flux (Newsholme EA and 
Randle PJ., 1964). PDK4 is also inhibited by increased acetyl-CoA to free CoA, 
nicotinamide adenine dinucleotide phosphate hydrogen (NADPH) to nicotinamide 
adenine dinucleotide (NAD) or oxidized nicotinamide adenine dinucleotide phosphate 
(NADP
+
) ratios produced by high rates of FAO, thus further inactivating PDH. The 
augmented acetyl-CoA to free CoA ratio also causes the build-up of intracellular citrate 
and this can block PFK and glycolysis (Kim JK et al., 2004; Holness MJ and Sugden 
MC., 2003). This results in activation of PDK4 and phosphorylation of PDH to its 
inactive form (Bowker-Kinley MM et al., 1998; Holness MJ and Sugden MC., 2003). 
In addition, acetyl-CoA inhibits the rate of flux through active dephosphorylated PDH.  
 
 
 
 
 
 
 
 
 
Figure 1.3 The Randle cycle showing the interrelationship between myocardial fatty acid 
and glucose metabolism. IRS/PKB (insulin receptor substrate/protein kinase B); PFK-1 
(phosphofructokinase-1); PDH (pyruvate dehydrogenase); PDK (pyruvate 
dehydrogenase kinase); CPT-I (carnitine palmitoyl transferase-I); PPAR-α (peroxisome 
proliferator-activated receptor-α); NADH (nicotinamide adenine dinucleotide hydrogen); 
FAs (fatty acids). modified from An D and Rodrigues B., 2003 
Thus in some pathophysiogical disease states (e.g. diabetes and myocardial infarction) 
high FA utilization impairs glucose utilization thereby contributing to hyperglycemia and 
insulin resistance (Jagasia D et al., 2001; Maki M et al., 1997). In addition, as the heart 
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adapts to high FA consumption for ATP generation there is a decreased cardiac efficiency 
since more oxygen will be consumed with less energy produced. This increases the risk of 
cardiac dysfunction especially during ischemia when reduced oxygen supply is available 
for FAO. Furthermore, under these conditions the heart also increases its dependence on 
glucose as fuel substrate (Derave W et al., 2000; Jensen J et al., 1997). 
However, the heart has the ability to promptly switch substrate selection in order to 
accommodate diverse physiological and pathological conditions involving extracellular 
hormones, substrate availability and workload (energy demand) (Ashrafian H., 2011; 
Hausenloy DJ., 2012). Although switching of substrates guarantees that a continuous 
ATP generation is provided to retain heart function, it is also associated with detrimental 
effects such as decreasing cardiac efficiency. Cardiac efficiency is the amount of work 
produced by the heart per energy (oxygen) consumed. It is dependent not only on the 
efficiency of producing ATP but also on the efficiency of using energy to produce 
contractile work (Ashrafian H., 2011). FAs are therefore less efficient as more oxygen is 
required to produce ATP. If the FA supply to the heart rises, assuming sufficient oxygen 
availability (non-ischemic conditions), the rate of FAO increases and glucose oxidation 
(GO) decreases; followed by FAO inhibiting GO (Ashrafian H., 2011). Therefore in 
certain conditions were circulating free FAs are elevated, e.g. ischemia and T2DM, there 
can be a decrease in cardiac efficiency (Hausenloy DJ., 2012). The next section will now 
focus on substrate metabolism under pathophysiological conditions of interest in this 
thesis i.e. diabetes/hyperglycemia and MI as well as I/R.  
1.8 Alterations of cardiac metabolism during diabetes/ hyperglycemia 
Hyperglycemia is a common symptom for all types of diabetes and is the main risk factor 
predisposing to the development of micro- and macrovascular complications (Luiken JJ 
et al., 2003; Sowers JR et al., 2001; Wilson PW., 2001). There are two forms, i.e. 
chronic hyperglycemia (diabetes) and acute hyperglycemia that can occur in both diabetic 
and non-diabetic individuals (Stanley W et al., 2005; United Kingdom Prospective 
Diabetes Study (UKPDS) Group., 1998). Hyperglycemia is a consequence of decreased 
glucose clearance and augmented hepatic glucose production, as a result of decreased of 
glucose to glycolysis thereby resulting in a reduction in GO (Carroll R et al., 2005; 
Young ME et al., 2002). The impaired recruitment of GLUT4 to the cell membrane upon 
insulin stimulation that may occur as a result of alterations in the insulin receptor 
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substrates (IRS)/phosphoinositide-3 kinase (PI 3-K)/PKβ also known as Akt signaling 
pathway is also implicated (Clerk LH et al, 2002; Young ME et al., 2003). Together 
with this (especially with chronic hyperglycemia), enhanced lipolysis in adipose tissue 
and higher hepatic lipoprotein synthesis can dramatically increase circulating free FAs 
and TG (Clerk L.H et al, 2002).  The outcome of hyperglycemia on the heart is described 
in the section below. 
1.9 Detrimental effects of hyperglycemia related to the development of 
CVD 
The chronic activation of such mechanisms (as discussed above) can lead to the onset of 
diabetic cardiomyopathy. Diabetic cardiomyopathy is characterized by ventricular 
dysfunction that occurs independently of coronary artery disease and hypertension (An D 
and Rodrigues B., 2003).  This condition is characterized by an increased stiffening of 
the left ventricular wall with associated accumulation of connective tissue and insoluble 
collagen (Anguera I et al., 1998; Rodrigues B et al., 1995; Saito F et al., 2003) and 
irregularities of numerous proteinsthat control ion flux, specifically intracellular calcium 
(Golfman LS et al., 1996; Tahiliani AG and McNeill JH., 1986). The underlying 
causes of the diabetic cardiomyopathy remain unclear, although several studies indicate 
that it could also arise as a consequence of various metabolic alterations such as 
hyperglycemia (Lopaschuk GD., 1989; Lopaschuk GD., 2002; Lopaschuk GD et al., 
1994).  
Hyperglycemia can contribute to the progress of vascular complications through 
numerous mechanisms such as activation of the 1) polyol and 2) hexosamine pathways, 3) 
activation of diacylglycerol (DAG) - PKC, 4) increased oxidative stress and 5) the 
enhanced production of advanced glycation end-products (AGEs) (Ohnishi T et al., 
2005; Wendt T et al., 2006; Koya D et al., 1997; Brownlee M., 2001). These 
mechanisms induce endothelial and cardiomyocyte dysfunction and will be later 
discussed. In support for this role, recent epidemiological studies demonstrated that 
chronic hyperglycemia is an independent risk factor for coronary heart disease; although 
the exact mechanism(s) underlying this association are not completely clear (Duckworth 
W et al., 2009; Home P et al., 2009). Abundant experimental evidence from animal 
studies shows that acute hyperglycemia blunts endothelium-dependent vasodilatation in 
isolated aortas from normal and diabetic animals (Kuusisto J et al., 1995; Durante W et 
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al. 1988). Acute MI is the major contributor to cardiovascular deaths with diabetes and it 
often progresses into end-stage heart failure (HF) (Ishihara M et al., 2003). Furthermore, 
stress-induced, acute hyperglycemia in non-diabetic patients with acute MI is associated 
with increased in-hospital deaths (Masaharu I., 2012). This implies that the affliction of 
diabetes still warrants much attention and requires a complete understanding of the basic 
molecular mechanisms as it will allow the development of effective, novel therapies 
which would aim to reduce the development of the diabetic related complications. To 
further understand the effects of hyperglycemia, the next section discusses some of the 
mechanisms whereby hyperglycemia can lead to CVD development.  
1.10 Hyperglycemia-induced effects and CVD onset 
1.10.1 Hyperglycemia induced oxidative stress 
Both chronic and acute hyperglycemia may mediate damaging effects through a sequence 
of secondary transducers, particularly ROS (Jaswal JS et al., 2011). Oxidative stress 
exists when the production of ROS is greater than its removal by intracellular antioxidant 
systems (Jaswal JS et al., 2011). The resultant elevation of ROS has ample deleterious 
effects on the cardiovascular system e.g. cellular damage by oxidation; disruption of 
vascular hemostasis through interference with nitric oxide (NO), and by modulation of 
detrimental intracellular signaling pathways (Brownlee M., 2001). Although under 
physiologic states most intracellular ROS arise from mitochondria, this may be different 
within the context of disease onset (Boudina S, Abel ED., 2007). For example, the 
NADPH oxidase enzymes are also known as ROS generators. These enzymes act as 
catalysts for electron transfer from NADPH to molecular oxygen, resulting in the 
generation of free radicals (Li L and Renier G., 2006). Through interaction with an 
assortment of transcription factors, redox signaling impacts the expression of growth-
related genes and in turn disturbs contractile function. A surge in ROS also leads to 
deoxyribosnucleic acid (DNA) damage and activation of poly (ADP ribose) polymerase 
(PARP) as a reparative enzyme (Ihnat M et al., 2007). There is also evidence that greater 
cytosolic ROS generation fuesl mitochondrial ROS overproduction, which underscores 
the pathogenic prominence of ROS generation from non-mitochondrial sources (Ihnat M 
et al., 2007; Zhou L et al., 2010).  
As discussed earlier, mitochondrial ROS is usually the major source of oxidative stress 
associated with hyperglycemia. Here more glucose is oxidized in the CAC cycle, which 
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drives greater electron input [NADH and FADH2 (flavin adenine dinucleotide, reduced)] 
into the electton transport chain (ETC). There are four protein complexes in the 
mitochondrial electron transport chain, called complex I, II, III, and IV (Figure 1.4). 
When glucose is metabolized through the CAC, it generates electron donors (Chen Y et 
al., 2005; Genova M et al., 2001). The main electron donor is reduced nicotinamide 
adenine dinucleotide (NADH), which provides electrons to complex I (Carroll J., 2005). 
The other electron donor generated by the CAC cycle is FADH2, formed by succinate 
dehydrogenase, which donates electrons to complex II (Cecchini G., 2003). Electrons 
from both these complexes are passed to coenzyme Q, and then transferred to complex 
III, cytochrome-C, complex IV, and finally to molecular oxygen, to then be reduced to 
water (Wallace DC., 1992). The ETC is organized in this way so that the level of ATP 
can be precisely regulated. This generates what is in effect a voltage across the inner 
mitochondrial membrane. The energy from this voltage gradient drives the synthesis of 
ATP by ATP synthase (Wallace DC., 1992; Trumpower BL., 1990). Alternatively, 
uncoupling proteins (UCPs) (Figure 1.4) keeps the rate of ATP generation constant 
through this process.  
Under hyperglycemic conditions the voltage gradient across the mitochondrial membrane 
increases until a critical threshold is reached due to the excess electron flux via NADH 
and FADH2. At this point the electron transfer inside complex III is blocked (Korshunov 
SS et al., 1997), causing the electrons to build up in coenzyme Q, and thereby generating 
superoxide (Figure 1.4). The mitochondrial isoform of the enzyme superoxide dismutase 
(SOD) usually degrades this to hydrogen peroxide, which is then converted to water and 
oxygen. ROS produced can also damage the ETC producing complexes itself thereby 
further decreasing its activity and exacerbating free radical production (Brand M et al., 
2004).  
ROS production from either mitochondrial and/or non-mitochondrial sources can 
generate the following products, i.e. the superoxide radical (O2
●-
), hydrogen peroxide 
(H2O2), and hydroxyl radical (OH
●-
). The hydroxyl radical can be formed in the presence 
of copper or iron by the amalgamation of O2
●-
and H2O2 (Argirova M and Ortwerth B., 
2003; Eaton J et al., 2002).  Increased ROS levels are not only the consequence from its 
overproduction, but may also manifest due to reduced efficacy of inhibitory scavenger 
systems (Argirova M and Ortwerth B., 2003). The endogenous oxidative stress defense 
mechanisms are stunted during extreme conditions such as hyperglycemia and/or 
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ischemia-induced oxidative stress (Dhar A et al., 2008). Such antioxidant mechanisms 
include both glutathione reductase and peroxidase that are involved in the recycling of 
glutathione (GSH) in its reduced and oxidized form glutathione disulfide (GSSG) 
(McCord J and Edeas M., 2005). Glutathione peroxidase eliminates hydrogen peroxide 
by oxidizing GSH into GSSG, which acts as an antioxidant by changing GSSG to GSH 
(McCord J and Edeas M., 2005). SOD is another antioxidant that converts superoxide to 
H2O2. SOD can present in three isoforms, i.e. SOD1; a dimer occurring in the cytoplasm, 
while SOD2 and SOD3 are tetramers found in the mitochondrion and extracellular 
matrix, respectively (McCord J and Edeas M., 2005). The generation of superoxide 
leads to events resulting in the inhibition of the glycolytic enzyme glyceraldehyde-3-
phosphate dehydrogenase (GAPDH), causing increased flux of glycolytic metabolites 
through the non-oxidative glucose pathways which will be discussed below. 
 
Figure 1.4 The production of superoxide (O2
●-
) by mitochondrial complex I and III15. 
Free electrons leaked from the electron transport chain during oxidative respiration, 
allow for the formation of O2
●-
 from molecular oxygen in complex I and III. O2
●-
 
generated from complex I get converted to hydrogen peroxide (H2O2) by manganese 
superoxide dismutase (MnSOD) in the mitochondrial matrix. O2
●-
 generated by complex 
III undergoes a similar fate, but also gets translocated to the cytosol where it is converted 
to H2O2 by copper/zinc superoxide dismutase (Cu/Zn SOD). SOD – superoxide dismutase 
modified from An D and Rodrigues B., 2003 
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1.10.2 Hyperglycemia-induced non-oxidant pathway activation 
Several animal and human studies have shown that with hyperglycemia there is a 
decrease in the activity of the key glycolytic enzyme GAPDH due to ROS production 
(Boudina S et al., 2007). As shown in Figure 1.5, the intracellular levels of several 
glycolytic intermediates (upstream of GAPDH) consequently increase. This in turn can 
activate two of the four pathways, i.e. the 1) AGE pathway because the major 
intracellular AGE precursor methylglyoxal is formed from glyceraldehyde-3 phosphateas, 
and the 2) PKC pathway, since the activator of PKC, DAG, is also formed from 
glyceraldehyde-3 phosphate. However further upstream, levels of the glycolytic 
metabolite fructose-6 phosphate increase thereby enhancing flux through the 3) 
hexosamine pathway, where fructose-6 phosphate is converted by the enzyme glutamine: 
fructose-6-phosphate amidotransferase (GFAT) to uridine diphosphate acetylglucosamine 
(UDP-GlcNAc) (Du X et al., 2003). Finally, inhibition of GAPDH increases intracellular 
glucose levels that elevates flux through the 4) polyol pathway, where the enzyme aldose 
reductase converts glucose to sorbitol, consuming NADPH in the process. These 
pathways are briefly explained below as they are not the focus of this project. 
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Figure 1.5 Mitochondrial overproduction of superoxide activates four major pathways of 
hyperglycemic damage by inhibiting GAPDH. NADH (nicotinamide adenine dinucleotide 
hydrogen); NAD+ (oxidized nicotinamide dinucleotide); GAPDH (glyceraldehyde-3-
phosphate dehydrogenase; PARP (poly(ADP)ribose polymerase); O2●- (superoxide 
radical); NADPH (nicotinamide adenine dinucleotide phosphate hydrogen); NADP 
(oxidized nicotinamide adenine dinucleotide phosphate); GFAT (glutamine:fructose-6-
phosphate amidotransferase); UDP (uridine diphosphate); AGEs (advanced glycation 
end products); DHAP (dihydroxyacetone phosphate); DAG (diacylglycerol); PKC 
(protein kinase C). American Diabetes Association. Diabetes, 2005 
1.10.2.1 Polyol pathway 
Here the enzyme aldose reductase reduces the aldehyde form of glucose to sorbitol. 
Sorbitol is then oxidized to fructose by sorbitol dehydrogenase and enters glycolysis. 
However, with hyperglycemia there is an increase in sorbitol levels which may exert 
various detrimental effects. These include deregulation of the cellular osmotic status, 
reduction of sodium/potassium (Na
+
/K
+
) -ATPase activity, increased cytosolic 
NADH/NAD
+
, and decreased cytosolic NADPH leading to increased ROS production, 
Ultimately vascular complications occur through the action of aldose reductase (Lou MF 
et al., 1988; Obrosova IG et al., 1999).  
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1.10.2.2 Hexosamine pathway 
With the hexosamine pathway, fructose 6-phosphate is converted into N-
acetylglucosamine a substrate for proteoglycan synthesis and results in the formation of 
O-linked glycoprotein. N-acetylglucosamine is implicated in the activation of the 
transcriptional factor specificity protein 1(Sp1) which increases synthesis of growth 
factor-[beta] 1 and plasminogen activator inhibitor-1 associated with development of 
vascular complications as well as increased oxidative stress (Han I & Kudlow J., 1997). 
1.10.2.3 DAG-PKC pathway 
Hyperglycemia can stimulate de novo synthesis of diacylglycerol (DAG), followed by the 
activation of PKC. This in turn induces changes in endothelial permeability, 
vasoconstriction, increased synthesis of extracellular matrix, and stimulation of cytokine 
synthesis, cell growth, angiogenesis, and leukocyte adhesion (Koya D et al., 2000). PKC 
modulates various enzymes including, phospholipase A2, Na
+
/K
+
 -ATPase (Koya D et 
al., 2000). 
1.10.2.4 Advanced glycation end-products and associated receptors 
Proteins and lipids may become non-enzymatically glycated and oxidized when in 
subsequent contact with aldose sugars, resulting in AGEs formation as a product of the 
Maillard reaction - (Singh R et al., 2001). The reducing sugars in the Maillard reaction 
react with amino groups of proteins to produce a Schiff base. Molecular rearrangements 
result in more stable Amadori products (ketoamine). Further rearrangements, 
condensations and dehydrations result in the formation of intermediate α-oxoaldehydes 
such as methylglyoxal (MG) and 3-deoxygluosone (Gkogkolou P and Böhm M., 2012). 
MG can also be made via non-oxidative mechanisms in anaerobic glycolysis (Thornalley 
PJ., 1996), and the oxidative breakdown of polyunsaturated FAs inducing oxidative stress 
and cell death (Okado A et al., 1996; Zarubin T and Han J., 2005). 
AGE-related injuries can occur via three possible mechanisms: firstly, AGEs can 
accumulate in the extracellular matrix resulting in cross-link formation, causing blood 
vessels to become narrower and stiffen (as in atherosclerosis) (Yamagishi S and 
Imaizumi T., 2005). Secondly, AGEs can have an effect on signaling pathways through 
AGE-mediated glycation of intracellular proteins, e.g. intracellular AGEs decrease 
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endothelium nitric oxide synthase (eNOS) activity resulting in defective vasodilation 
(Bucala R et al., 1991). MG is also a precursor of intracellular AGEs which alter 
antioxidant systems causing increased oxidative stress (Bucala R et al., 1991). Lastly, the 
interaction between AGEs and its receptors (RAGEs), leads to the stimulation of 
downstream signaling cascades, resulting in  increased ROS generation via NADPH 
oxidase (NOX) activation (Basta G et al., 2004). The enhancement of oxidative stress 
and stimulation of cytokines and growth factors lead to the acceleration of chronic 
inflammation and endothelial dysfunction as well as development of vascular diabetes 
complications (Basta G et al., 2004). 
Together this indicates that mitochondrial and non-mitochondrial ROS are key players in 
the manifestation of cardio-metabolic pathophysiologies. Here the initiating event is 
mitochondrial superoxide production that triggers further ROS generation (other sources) 
thereby creating a vicious cycle. Subsequently, ROS can induce cellular damage by 
various mechanisms. Therefore it is important to understand the molecular mechanisms of 
events which occur during acute myocardial infarction (AMI) under hyperglycemic 
conditions and how this can result in myocardial damage.  
1.11 Metabolic changes during ischemia and reperfusion 
As stated before, most of the heart’s energy requirements are derived from the oxidative 
phosphorylation of metabolic fuel substrates. Thrombosis or atherosclerosis causes 
myocardial ischemia resulting in minor or severe deficiency of coronary blood flow from 
the large arteries to the myocardium thus leading to an oxygen-deprived myocardium, 
fuel substrates and the build-up of metabolites (Park J and Lucchesi B, 1999) and 
ultimately triggering cell death within the infarcted area (Mochizuki S and Neely R, 
1979; Solaini G and Harris DA, 2005). Ischemic conditions also alter cardiac structure, 
function and perturbations in energy substrate metabolism influencing FA and GO. There 
is a rapid loss of contractile force and disturbances in ionic homeostasis due to lack of 
blood supply to the heart. Alterations in oxygen and substrate availability in turn change 
mechanisms regulating substrate metabolism hence affecting cardiac efficiency (Kim AS 
and Johnston SC, 2011). Prominent alterations in energy metabolism occur in the setting 
of myocardial ischemia, depending on the severity (mild to severe) and reperfusion 
resulting in a decrease in cardiac efficiency. The reduced oxygen availability attenuates 
both GO and FAO (Jaswal JS et al, 2011; Seifert EL et al, 2008).  
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Interestingly, during mild ischemia FAO dominates as the source of myocardial oxidative 
metabolism. It is important to note that unlike the normal heart, exposure of the ischemic 
heart to FAs does not hinder glycolysis. The glycolytic rates are raised in the ischemic 
heart (Lopaschuk GD., 1993); however chronic hyperglycemia can result in amplified 
ischemic metabolic changes due to the manifestation of altered metabolic dysfunction 
(Kannel WB and McGee DL., 1979).  This implies that the FA surplus (and 
intermediates e.g. fatty acyl-CoAs, DAG and ceramides) and attenuated GO found with 
diabetes or the metabolic syndrome (Lewandowski E and White L., 1995, Liedtke A et 
al., 1988) is further exacerbated during AMI since it manifests in the same way. 
Nevertheless there is a rise in glycolysis and diminished GO in the ischemic heart. This 
occurs due to elevation of glucose uptake by the myocardial cell membrane (Sun D et al., 
1994) that occurs by increased GLUT1/4 translocation and activity (Brosius III F et al., 
1997, Chen T et al., 1997) secondary to increased AMPK activation (Misra P and 
Chakrabarti R., 2007). The increase in glucose transport with decreased oxygen 
availability may be of physiological importance, i.e. allowing the heart to obtain more 
energy from glycolysis under conditions where FAO is predominant (Stanley WC et al., 
1997). However, increased FAO inhibits GO, resulting in an imbalance between 
glycolysis and GO (Saddik M and Lopaschuk G., 1991) resulting in lactate and proton 
accumulation in the ischemic myocardium.  
1.12 Ionic imbalances during ischemia and reperfusion 
The uncoupling of glycolysis from GO largely explains the acidosis observed in the 
severely ischemic heart.  Increased FAO results in a scenario where there is an 
accumulation of protons that can lead to sodium (Na
+
) and calcium (Ca
2+
) overload in the 
heart, resulting in decreased cardiac efficiency as ATP is used to restore ionic 
homeostasis (Ashrafian H., 2011). Furthermore, the decrease in intracellular pH is 
associated with a loss of troponin C sensitivity to PFK and Ca
2+
 resulting in contractile 
arrest and cellular bulging (Abe T et al., 2002; Belke DD et al., 2004, Choi KM et al., 
2002). Thus Na
+
 overload occurs as the myocardium tries to compensate for the fall in pH 
by excessively excreting hydrogen ion (H
+
) in exchange for Na
+
 influx by the 
sodium/hydrogen (Na
+
/H
+
) exchanger (Pike MM., 1993). On the other hand, intracellular 
ATP reduction gradually inactivates ATPases, such as the Na
+
/K
+
 ATPase, ATP-
dependent Ca
2+
 reuptake, and actives Ca
2+
 excretion, resulting in Ca
2+
 overload. This 
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causes a fragile cellular structure, hypercontracture, which leads to contraction band 
necrosis, and the initiation of apoptotic cascades (Schäfer C., 2001) due to the 
uncoupling of glycolysis under ischemic events.  
Upon reperfusion, speedy normalization of the extracellular pH will promptly create an 
extreme H
+
 gradient across the plasma membrane that generates a robust Na
+
/H
+
 
exchange and a massive Na
+
 influx, leading to Ca
2+
 overload. Meanwhile, rapid 
normalization of intracellular pH disinhibits a low pH-derived inhibition of the 
Ca
2+
dependent protease calpain, hypercontracture, and the mitochondrial permeability 
transition all at once and promptly hastens myocardial damage in the initial stages of 
reperfusion (Hausenloy D ., 2012). Although there is no doubt that reperfusion does 
indeed salvage the ischemic myocardium, it can paradoxically also induce some 
detrimental effects, i.e. a phenomenon referred to as ‟ischemia/ lethal reperfusion injury‟ 
(Sanada S et al., 2011; Hausenloy D., 2012) discussed below 
1.13 Myocardial reperfusion injury 
Reperfusion injury refers to myocardial, vascular, or electrophysiological dysfunction that 
is induced by the restoration of blood flow to previously ischemic tissue and was first 
postulated by Jennings et al. in 1960.  
He proposed that during myocardial reperfusion, the acute ischemic myocardium is 
subjected to numerous unexpected biochemical and metabolic changes, which compound 
the fluctuations generated during the period of myocardial ischemia. These changes 
include mitochondrial re-energization, the generation of ROS, intracellular Ca
2+
 overload, 
the rapid restoration of physiologic pH, and inflammation, all of which cross-interacts 
with each other to mediate cardiomyocyte death through the opening of the mitochondrial 
permeability transition pore (PTP) and the induction of cardiomyocyte hypercontracture. 
During myocardial reperfusion, ROS is generated by xanthine oxidase (mainly from 
endothelial cells) and the re-energized ETC in cardiomyocyte mitochondria. Free radicals 
damage myocytes directly by altering membrane proteins and phospholipids (Zweier JL., 
1988). Because these membrane constituents play crucial roles as receptors, enzymes, and 
ion channels, free radical injury can lead to fatal metabolic and structural derangements. 
For example, radicals injure the sarcolemma and may impair contractile function of the 
myocyte (Hearse DJ et al., 1973). The role for free radicals as a source of significant 
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myocardial damage is further supported by studies showing that free radical scavengers, 
such as SOD, administered during thrombolytic therapy, help preserve myocardial 
function (Flaherty JT et al., 1994). However, several hours later NADPH oxidase 
(source of ROS mainly from neutrophils) stimulates leukocyte activation, chemotaxis, 
and leukocyte-endothelial adherence (Zweier JL., 1988; Hearse DJ et al., 1973). 
The neutrophil accumulation in non-perfused microvessels and complement activation 
may contribute to the "no-reflow" phenomenon (Ito H., 2003; Piper HM et al., 1988). 
Once in the extravascular space, leukocytes can release proteases and elastases that 
destroy the cell membrane and cause cell death (Piper HM et al., 1988; Keeley EC et al., 
2003). However, the roles of the various inflammatory mediators are complex and 
incompletely understood. Although they play a role in reperfusion injury, some also 
appear to have cardioprotective effects (Vinten-Johansen J., 2004; Zhao ZQ et al., 
1997). Terminal complement cascade species directly injure the endothelium, rendering it 
incapable of producing vasodilatory compounds such as NO. This perpetuates a cycle of 
vasoconstriction and reduction in microvascular perfusion, leading to apoptosis not only 
within the infarct area, but also in the border zone (Zweier JL., 1988; Ly HQ et al., 
2005). 
ROS also mediates myocardial injury  by inducing mitochondrial permeability transition 
pore (mPTP) opening already, acting as neutrophil chemoattractants, mediating 
dysfunction of the sarcoplasmic reticulum and contributing to intracellular Ca
2+
 overload, 
damaging the cell membrane by lipid peroxidation, inducing enzyme denaturation, and 
causing direct oxidative damage to DNA (Bär F;W et al., 2006). Furthermore, the 
restoration of the mitochondrial membrane potential drives the entry of Ca
2+
 into 
mitochondria that in conjunction with the loss of the inhibitory effect of the acidic pH on 
the mPTP and the generation of ROS, act in concert to mediate the opening of the mPTP 
(Idem., 2003; Gumina RJ., 1999). This opening induces cardiomyocyte death by 
uncoupling oxidative phosphorylation and inducing mitochondrial swelling.  
During myocardial reperfusion, the rapid washout of lactic acid together with the function 
of the Na
+–H+ and sodium bicarbonate (Na+–HCO3) transporters mediate the rapid 
restoration of physiologic pH, and also facilitating mitochondrial PTP opening and 
cardiomyocyte hypercontracture (Zeymer U et al., 2001). Several hours after the onset of 
myocardial reperfusion, neutrophils accumulate in the infarcted myocardial tissue in 
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response to the release of the chemoattractants ROS, cytokines, and the activated 
complement pathway. The up-regulated cell-adhesion molecules P-selectin and 
complement receptors consisting of CD18 (intergrin β2) and CD11b (integrin αM), and 
intracellular adhesion molecule 1 (ICAM-1) then facilitate the migration of neutrophils 
into the myocardial tissue, where they mediate cardiomyocyte death by causing vascular 
plugging, releasing degradative enzymes, and generating ROS (Mertens P et al., 2006; 
Tanguay JF et al., 2004).  
1.14 Various modes of cell death in CVDs 
While ischemic damage occurs principally through necrosis, reperfusion injury may also 
manifest as a result of apoptosis (Kajstura J et al., 1996). For example, markers of 
apoptosis found in reperfused tissue were not present in normal tissue or tissue injured 
solely by ischemia (Fliss H and Gattinger D., 1996). Others have reported the 
appearance of apoptotic cells in the peri-necrotic zone during reperfusion (Lee P et al., 
2003) and suggested that understanding the different contributions of necrosis and 
apoptosis to reperfusion injury may help identify novel treatment strategies (Bhuiyan MS 
and Fukunaga K., 2007). A link between reperfusion and apoptosis is supported by 
studies demonstrating the role of magnesium-dependent SOD and O2
●- 
formation in the 
activation of pro-apoptotic factors. An apoptosis repressor is capable of inhibiting this 
process and reducing the extent of myocardial infarction (Fliss H and Gattinger D., 
1996). Cardiomyocytes respond to stress by the accumulation of protective proteins that 
may counteract damage, thereby temporarily increasing tolerance to such damage.  On the 
other hand, it may trigger programmed cell death (apoptosis) to remove terminally 
damaged cells (Anversa P et al., 1998, Bhuiyan MS and Fukunaga K., 2007) which 
can be eliminated by the ubiquitin proteasome system and/or lysosomal-autophagal 
system. We will next discuss the various modes of cell death that may occur in various 
cardiac diseases e.g. HF, diabetic cardiomyopathy, AMI, and I/R. The modes of cell death 
discussed are autophagy, apoptosis, and necrosis as they are present in various CVDs of 
interest to us AMI; however, for this thesis apoptosis is of particular interest.  
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1.14.1 Necrosis 
Necrosis is recognized by distinctive morphological changes, including cell swelling, 
plasma membrane damage, loss of ATP, and organelle swelling. The disturbance of cell 
integrity and release of cellular content leads to a secondary inflammatory response, with 
potential pathological consequences (Whelan RS et al., 2010). Necrosis is usually 
activated by physical or chemical distress to the cell and has been thought to be a passive 
and accidental form of cell death (Vanlangenakker N et al., 2008). In recent times, 
growing evidence suggests that a portion of necrosis is regulated by serial signaling 
events in an exact and orchestrated manner. Numerous terms have been introduced to 
describe this form of necrosis, such as programmed necrosis, caspase-independent cell 
death, and necroptosis (Henriquez M et al., 2008). Numerous mechanisms have been 
linked to describe the initiation and execution of necrosis, including death receptors, 
ROS, Ca
2+
, and mPTP opening (Kroemer G et al., 2007; Vanlangenakker N et al., 
2008). 
The ionic imbalances that occur in certain pathologies such as I/R (refer to section 1.12) 
and the associated mitochondrial swelling and membrane rupture (Schäfer C., 2001) 
result in necrotic cell death (Whelan RS et al., 2010). Moreover, increased H
+
 in the 
cytoplasm and inactivation of H
+
 pumps elicit declines in lysosomal pH, which results in 
over-activation of proteases such as cathepsins. The substantial entry of water into 
lysosomes causes swelling, membrane rupture and the release of proteases into the 
cytoplasm. Together with other activated proteases, such as calpains, this can digest 
different substrates, including cytoskeletal proteins, contributing to necrosis (Henriquez 
M et al., 2008). The activation of death receptors, such as the tumour necrosis factor 
alpha (TNF-α) receptor, represents other necrotic pathways in cardiac myocytes under 
certain conditions such as HF. The activation of such receptors could lead to the 
activation of receptor-interacting protein (RIP), increased ROS, and necrosis. However, 
with myocardial infarction there remains disagreement concerning the leading mode of 
cell death i.e. necrosis, apoptosis, and autophagy (Baines C et al., 2005; Gottlieb R et 
al., 1994). 
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1.14.2 Apoptosis 
Apoptosis is an active evolutionarily conserved form of cell self-destruction.  Cells 
undergoing apoptosis become fragmented and form apoptotic bodies. These are then 
recognized by macrophages and cleared from the tissue to avoid inflammatory responses. 
Apoptosis is facilitated in two ways, the extrinsic and the intrinsic pathways, and both 
have been described in cardiac myocytes (Kerr J et al., 1972; Kroemer G et al., 2005).  
1.14.2.1 Extrinsic /external/death receptor pathway 
The external pathway is triggered by binding of death ligands to cell surface receptors 
(endonucleases). The best recognized receptors are those for TNF-α and Fas also named 
apoptosis antigen 1(APO-1) ligand receptor (Peter M and Krammer P., 2003). The 
stimulated death receptor then transfers signals to the Fas-associated death domain 
protein (FADD). The Fas and TNF-α receptors are then expressed in cardiac myocytes 
and implicated in cardiovascular pathology. Since TNF-α signaling is more complex due 
to the fact that it can either promote survival or death; events following binding of Fas 
ligand are defined. The death receptor activation by a death ligand induces death-inducing 
signaling complex (DISC) formation and caspase-8 activation, which in turn activates 
caspase-3 (Ashkenazi A., 2002).  
1.14.2.2 The intrinsic/mitochondrial pathway 
As its name suggests, the intrinsic (or mitochondrial) pathway is initiated from within the 
cell. It is activated in response to signals resulting from DNA damage, loss of cell-
survival factors, or other types of severe cell stress. Because mitochondria can also 
contribute to cell death in response to multiple stresses, cardiac myocytes have developed 
special strategies to achieve strict control over the intrinsic apoptotic pathway (Whelan 
RS et al., 2010; Lee Y and Gustafsson AB., 2009). Normally, pro-apoptotic proteins are 
released from mitochondria to activate caspase proteases and trigger apoptosis (Cotter 
T.G., 2009) (Figure 1.6). The intrinsic pathway is activated by the proteolysis of B cell 
leukemia/lymphoma-2 (Bcl-2) - homology domain 3 (BH3) -only interacting protein 
domain (BID) to truncated BID (t-BID) by caspase-8 and interaction of t-BID with Bcl-2-
associated X protein (BAX) in the mitochondria. Pro-apoptotic Bcl-2-associated X 
protein/ Bcl-2 homologous antagonist /killer (BAX/ BAK) induces cytochrome c, second 
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mitochondria-derived activator of caspase/direct inhibitor of apoptosis (IAP)-binding 
protein with low PI (Smac/DIABLO), apoptosis inducing factor (AIF), and Endo G 
release from the mitochondria. Cytochrome c together with adaptor protein apoptotic 
protease activating factor-1 (Apaf1) and caspase-9 form the apoptosome with the 
activation of caspase-9. Caspase activity, however, is controlled by the endogenous 
caspase inhibitor X-linked inhibitor of apoptosis protein (XIAP). Cardiac myocytes are 
naturally less vulnerable to apoptosis because of their low-level expression of Apaf1 and 
caspases and high levels of XIAP (Ashkenazi A., 2002) (Figure 1.6). 
 
 
 
Figure 1.6. Apoptotic pathway in cardiomyocytes. Bax (Bcl-2-associated X protein),Bcl-2 
(B cell leukemia/lymphoma-2), Bid (BH3 -only interacting protein domain), tBid 
(truncated BID), Apaf-1 (adaptor protein apoptotic protease activating factor-1) 
modified from Russell S et al., 2010 
When such pro-apoptotic signals are not released, cells are unable to die (Cotter TG., 
2009). The intrinsic pathway hinges on the balance of activity between pro- and anti-
apoptotic signals of the Bcl-2 family (Vogler M et al., 2009). Pre-clinical studies indicate 
that members of the Bcl-2 family regulate the permeability of the mitochondrial 
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membrane and determine whether a pro- or anti-apoptotic signal will be released inside 
the cell (Mayer B and Oberbauer R., 2003). Research implies that in this cascade, the 
anti-apoptotic proteins [e.g. B cell leukemia/lymphoma-x-isoform (Bcl-xL)] antagonize 
Bax and Bak by binding to their BH3 domains. This antagonism is relieved by BH3-only, 
pro-apoptotic proteins [e.g., Bcl-2 like protein 11 (BIM), BH3-only interacting protein 
domain (BID), Bcl-2 associated death promoter (BAD)], which alternately bind to anti-
apoptotic proteins, like Bcl-xL. In normal cells, cellular stress would result in an 
upregulation of these BH3-only proteins in order to initiate apoptosis via the intrinsic 
apoptotic pathway (Lessene G et al., 2008). 
Activation of the mitochondrial apoptotic pathway leading to executioner caspase 
activation is relevant with heart injuries (Whelan RS et al., 2010), emerging from studies 
using immunofluorescence microscopy (Lee Y, Gustafsson AB., 2003). Bae et al. 2010 
reported that apoptosis can be induced in the heart lacking caspase activation via caspase-
independent pathways, probably through apoptosis inducing factor (AIF). Although it has 
been described that AIF is released from cardiac myocyte mitochondria during I/R, its 
contribution to I/R-induced apoptosis was discounted (Bahi N et al., 2006). However, 
AIF has been implicated in cardiac myocyte death induced by oxidative stress and HF 
(Chen M et al., 2004). Both the intrinsic and extrinsic pathways can be inhibited by the 
cytoprotective protein apoptosis repressor with caspase recruitment domain (ARC) 
(Gustafsson AB et al., 2004). Because of the intrinsically low levels of Apaf1 and 
caspases in cardiac myocytes, non-myocyte cells within the heart may be more 
susceptible to apoptosis (Bahi N et al., 2006, Gustafsson AB et al., 2004).  
The central role of intrinsic apoptosis in cardiac dysfunction following I/R has been 
reported in several studies. For example, cardiac myocyte-specific overexpression of Bcl-
2 substantially reduces infarct size, cardiac myocyte apoptosis, and cardiac dysfunction 
following I/R (Chen Z et al., 2001); Bax deficiency reduces infarct size and cardiac 
dysfunction following I/R and following MI in mice (Hochhauser E et al., 2007) and 
targeted deletion of PUMA, which is a BH3-only protein, reduced infarct size in an ex 
vivo Langendorff I/R model (Toth A et al., 2006). With regards to hyperglycemia, 
oxidative stress has been suggested to play a more central role in causing apoptosis, 
particularly when linked with mitochondrial dysfunction (Bhat N and Zhang P., 1999; 
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Buttke T and Sandstrom P., 1994). The last form of cell death is autophagy which will 
be discussed below. 
1.14.3 Autophagy 
The term autophagy means from the Greek “auto” or oneself and “phagy” or to eats. 
Involves the degradation of cellular components, either because they are deleterious (e.g., 
damaged organelles and microbial invaders) or because the resulting breakdown products 
are needed to support metabolism(Levine B, Kroemer G et al., 2008).Autophagy is one 
of the key cellular pathways that mediate’s stress-induced adaptation and damage control. 
It is a highly conserved process of delivering intracellular components (including 
mitochondria and long-lived macromolecules) to lysosomes for degradation via a double 
membrane structure called autophagosome (Levine B, Kroemer G et al., 2008). The 
expansion of autophagosome membranes involves Atg12 and Atg8 (called LC3 in 
mammals). Atg7 and E2-like Atg10 covalently link Atg12 with Atg5, which together bind 
Atg16L1 to produce pre-autophagosomal structures. LC3 is then cleaved by the protease 
Atg4. Phosphatidylethanolamine is conjugated to cleaved LC3 by Atg7, Atg3, this 
lipidated LC3-II associates with newly forming autophagosome membranes. LC3-II 
remains on mature autophagosomes until after fusion with lysosomes (Mizushima N., 
2007). Autophagy of depolarized mitochondria is initiated by Pink1-dependent 
mitochondrial translocation of Parkin. This is followed by ubiquitination of the 
mitochondrial proteins and recruitment of p62 to direct mitochondria to be 
autophagosised which can lead to cell death (Mizushima N., 2007). In eukaryotic cells 
and in cardiac myocytes, starvation/nutrient deprivation, hypoxia, ROS, damaged 
organelles, and protein aggregates have been shown to induce autophagy in a mammalian 
target of rapamycin (mTOR)-dependent process  (Levine B, Kroemer G et al., 2008; 
Marambio P et al ., 2010). Similarly, mTOR-independent autophagy has been reported; 
here, cytokines which do not exist in yeast, converge on type III phosphatidylinositol 3-
kinase to induce autophagy (Lipinski MM et al., 2010). Autophagy is a pro-survival 
mechanism that replenishes energy under stress conditions.  
The two pathways responsible for ischemia/hypoxia-induced autophagy are 
(Bcl2)/adenovirus E1B interacting protein 3 (BNIP3) or AMPK (Bahi N et al., 2006; 
Russell RR et al., 2004). In a mouse model conveying dominant-negative AMPK in 
cardiac myocytes, the autophagic response to ischemia was reduced, resulting in a larger 
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MI and worse cardiac function (Russell RR et al., 2004).  During reperfusion, autophagy 
is further upregulated, even though the delivery of oxygen and nutrients is restored and 
AMPK is rapidly inactivated (Matsui Y et al., 2004; Hamacher-Brady A et al., 2006). 
The continued activation of autophagy during reperfusion is qualitatively different to the 
ischemic context, especially in terms of mechanisms of induction (Hamacher-Brady A 
et al., 2006). For example, oxidative stress, mitochondrial damage/BNIP3, endoplasmic 
reticulum stress, and calcium overload, are likely to have more important roles in 
maintaining autophagy at a higher level during reperfusion (Russell RR et al., 2004) 
whereas with ischemia the main stimulators of autophagy are from different pathways 
such as  Beclin-1-mediated (Valentim L et al., 2006). Upregulation of autophagy can be 
either beneficial or detrimental within the context of I/R (Matsui Y et al., 2004; 
Hamacher-Brady A et al., 2006). One reason why this is the case is that during ischemia 
there is a decline in the levels of lysosome-associated membrane protein 2 (LAMP2), a 
protein critical for autophagosome–lysosome fusion, mediated by ROS-induced 
activation of serine and cysteine proteases; reperfusion induces upregulation of Beclin-1, 
which further impairs autophagosome processing, culminating in increased ROS 
generation, mitochondrial permeabilization, and cardiomyocyte death (Ma X et al., 
2011). More investigation is needed to clarify when and how elevated autophagy may be 
pro-survival to cardiac myocytes subjected to reperfusion injury. As a result, additional 
studies are essential to resolve such conflicting findings. 
1.14.4 Cross talk between the ubiquitin–proteasome system and 
autophagy 
A connection between the proteasome and autophagy systems has been established and is 
well documented, with studies establishing that ubiquitinated protein aggregates can be 
substrates for autophagic degradation (Komatsu M et al., 2007; Korolchuk VI et al., 
2009; Kirkin V et al., 2009). Various studies demonstrated that when the UPS is 
inhibited it leads to increased autophagy and vice versa (Ding WX et al., 2007; Hara T 
et al., 2006; Komatsu M et al., 2006). This is largely due to p62/SQSTM1 also known as 
sequestosome 1 that is an ubiquitin-binding scaffold protein that co-localizes with 
ubiquitin protein aggregates in many neurodegenerative diseases (Bjorkoy G et al., 
2009). It polymerizes via N-terminal polymerase basic 1 (PB1) domain and can interact 
with ubiqutinated proteins via the C-terminal ubiquitinated-associated domain (UBA) 
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domain (Bjorkoy G et al., 2009). Furthermore, it is able to bind directly with light chain 3 
(LC3) through specific motifs. It can be degraded by autophagy and may serve as a link 
for ubiquitinated proteins to the autophagic machinery; to eventually be degraded by the 
lysosome (Bjorkoy G et al., 2009). Evidence also exists that although the synchronized 
activity of these two systems are controlled by similar transcription factors, it is still 
functionally independent of one another (Zhao J et al., 2008; Zhao J et al., 2007). In 
vitro studies demonstrated that the accumulation of polyubiquitinated proteins was 
adequate enough to induce cardiomyocyte autophagy (Komatsu M et al., 
2007;Korolchuk VI et al., 2009; Kirkin V et al., 2009). The ubiquitin-binding protein 
nucleoporin p62 (p62) controls the formation of protein masses and is removed by 
autophagy. Neighbor of BRCA1 gene 1 protein (NBR1) is also recruited to ubiquitin-
positive protein aggregates and degraded by autophagy (Yamaguchi O et al., 2012). 
NBR1 and p62 can act as receptors for selective autophagosomal degradation of 
ubiquitinated targets (Yamaguchi O et al., 2012). These results propose a connection 
between the ubiquitin–proteasome system and autophagy. Even though cross-talk exists 
between autophagy and the lysosomal protein degradation, our attention is on the non-
lysosomal UPS and the part it plays in the degradation of proteins in the heart under 
hyperglycemic conditions withI/R. 
1.15 Structure and general function of the UPS 
Proteasomes are very large protein complexes found inside all eukaryotes, and their main 
function is to degrade surplus or damaged proteins by proteolysis, a chemical reaction 
that breaks peptide bonds (Lodish, 2004). The degradation process yields peptides of 
about seven to eight amino acids long, which can then be further degraded into amino 
acids and used for the synthesis of new proteins (Lodish, 2004). Therefore this process is 
vital for normal cellular function. The UPS also partakes in the degradation of misfolded 
and dislocated proteins from the endoplastic reticulum (ER) and therefore plays a key role 
in the cells’ response to ER stress and the removal of damaged proteins by oxidative 
stress (Grune T et al., 1997; Hershko A., 1991). The system is present within the 
nucleus and the cytosol, and here the proteins are marked for degradation by covalent 
linkage to multiple ubiquitin molecules, which is a multistep process (Zolk O et al., 
2006) (Figure 1.7).  
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Figure 1.7. The ubiquitin-proteasome pathway. Step 1: activation of ubiquitin by the ubiquitin 
activating enzyme E1, an ubiquitin-carrier protein, E2, and ATP, producing a high energy 
E2ubiquitin thiol ester intermediate. Step 2: binding of the protein substrate to a specific 
ubiquitin-protein ligase, E3. Step 3: multiple (n) cycles of ubiquitin conjugation, resulting in a 
polyubiquitin chain. Step 4: degradation of the substrate by the 26S proteasome complex with 
release of short peptides. Step 5: recycling of ubiquitin is recycled via deubiquitinating enzymes 
(DUBs) Zolk et al, 2006. 
Polyubiquitin chains are assembled via an isopeptide linkage between the lysine residue 
of the previous ubiquitin and the C-terminal glycine residue of the subsequent ubiquitin 
moeity.  Once marked by polyubiquitin chains, proteins are swiftly degraded by the 26S 
proteasome, which is a 2000-kDa ATP-dependent proteolytic complex (Zolk O et al., 
2006). The 20S proteasome is a C2-symmetric cylindrical complex consisting of a "core" 
of four stacked rings around a central pore. Each ring is composed of seven individual 
proteins. The inner two rings are made of seven β subunits that contain the six protease 
active sites. These sites are situated on the interior surface of the rings, so that the target 
protein must enter the central pore before it is degraded (Mearini G et al., 2008). 
However, eukaryotes lack enzymatic activity of the β3, β4, β6 and β7 but this loss is 
offset by the diverged substrate specificity of the remaining subunits. Of these, β1 also 
Step 1 
Step 2 
Step 3 Step 4 
Step 5 
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known as ‘caspase-like’ because it recognizes and processes substrates having acidic 
residues at position 1 (the amino acid occupying in the proteasome active site the position 
containing the scissile, a covalent chemical bond that can be broken by an enzyme, amide 
bond) (Jung T et al., 2009). The β2-subunit preferentially cleaves the C-terminus of basic 
amino acids and is also referred to ‘trypsin-like’, whereas β5 prefers hydrophobic 
residues and is referred to as ‘chymotrypsin-like’. The 19S proteasome contains two outer 
rings, each comprising seven α subunits whose function is to maintain a "gate" through 
which proteins enter the barrel. The α subunits are controlled by binding to "cap" 
structures or regulatory particles that identify the polyubiquitin tags attached to the 
protein substrates and initiate the degradation process. The overall system of 
ubiquitination and proteasomal degradation is known as the ubiquitin-proteasome system 
(Mearini G et al., 2008; Jung T et al., 2009). 
The 19S regulatory particle is responsible for stimulating the 20S unit to degrade proteins. 
A primary function of the 19S regulatory ATPases is to open the ‘’gate’’ within the 20S 
that usually blocks the entry of substrates into the degradation chamber. The mechanism 
by which the proteasomal ATPase opens this has recently been elucidated. Here the 20S 
gate opening, and thus substrate degradation, requires the C-termini of the proteasomal 
ATPases, which contains a specific motif (i.e. HbYX motif) (Jung T et al., 2009). The 
ATPases C-termini bind into pockets at the top of the 20S, and tether the ATPase 
complex to the 20S proteolytic complex thus joining the substrate unfolding equipment 
with the 20S degradation machinery. Binding of C-termini into 20S pockets by 
themselves excites the opening of the gate much like a "key-in-a-lock" opens a door. The 
precise mechanism by which this "key-in-a-lock" mechanism functions has been 
structurally revealed (Jung T et al., 2009). 
The conjugation of ubiquitin (Ub) to substrates usually involves three steps (refer Figure 
1.7): an initial activation step catalyzed by E1; an intermediate step in which the Ub is 
covalently linked to a conjugating enzyme, E2; and a final step where the Ub reaches its 
final destination of the substrate amino group (Zolk O et al., 2006). The last step is 
assisted by the E3 ligase enzyme family. Some types of E3s facilitate Ub conjugation to 
the substrate directly from E2 by acting as a bridging factor. Another type of E3 forms an 
Ub– thiol– ester intermediate before the ubiquitin is transported to the substrate. After the 
linkage of a polyubiquitin chain onto the protein that is to be degraded, its recognition 
occurs at the 19S cap of the 26S proteasome (Powell SR et al., 2006). The mechanism by 
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which a polyubiquitinated protein is targeted to the proteasome is not completely 
understood. However, the ubiquitin-receptor proteins contains an N-terminal ubiquitin-
like (UBL) domain and one or more UBA domains that are recognized by the 19S 
proteasome caps and bind ubiquitin via three-helix bundles, respectively (Herrmann J et 
al., 2004). These receptor proteins may aid the polyubiquitinated proteins towards the 
proteasome, though the specifics of this interaction and its regulation are uncertain. 
Degradation is brought about by the proteolytic activity of a pair of three different h-
subunits, h1, h2, and h5, each located in the cylinder of the 20S core unit of the 26S 
proteasome (Zolk O et al., 2006; Herrmann J et al., 2004. 
1.16 The cardiac 26S proteasome 
Cardiac proteins are in a dynamic state of constant degradation and re-synthesis. The 
cardiac proteasome has distinct properties with a specific molecular composition and 
post-translational modifications (Toth A et al., 2006), with substrate specificity mainly 
restin in the E3 ubiquitin ligases. Numerous cardiac E3 ligases including atrogin-1/ 
muscle atrophy F-box (MAFbx), muscle RING finger (MuRF), Hsp70-interacting protein 
(CHIP), and murine double minute 2  (MDM2) have already been implicated in the onset 
of cardiac diseases (Toth A et al., 2006).  Cardiac proteasome activity has also been 
found to decrease with age, as validated by increased oxidized and Ub proteins together 
with decreased 20S proteasome content and loss of specific activities. Loss of proteasome 
function may damage the ability of myocytes to elicitan appropriate response to stress, 
hence placing the ageing heart at risk for the development of cardiovascular diseases (Yu 
Yu X and Kem DC., 2010). In the heart the UPS regulates cardiomyocyte receptors and 
ion channels that play important roles in both health and disease (Yu X and Kem DC., 
2010). 
The UPS regulates cardiac membrane channels and receptors such as Connexin 43 and 
β2-adrenergic signaling (Hare JF et al., 1991; Li HH et al., 2004). Connexin 43 is a gap 
junction protein in ventricular myocardium.  The specifics of the molecular mechanisms 
by which gap junctions are targeted for degradation have not yet been clarified (Hare JF 
et al., 1991). The UPS also plays an essential role in modulating β-adrenergic receptors 
and G protein (heterotrimeric guanine nucleotide-binding protein)-coupled-receptor 
(GPCR) signaling pathways which stimulate guanine nucleotide binding protein G’s 
which control the L-type Ca
2+
channels, TnI, phospholamban, and ryanodine receptors (Li 
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HH et al., 2004). Stimulation of β2-adrenergic receptors (β2ARs) leads to quick 
ubiquitination of the β2AR receptor and the receptor regulatory protein, β-arrestin. 
Studies have found that proteasome inhibitors decrease receptor internalization and 
degradation, hence implicating a role for proteasome-dependent degradation in the 
exchange of the β2AR (Li HH et al., 2004).  
While most proteasomal substrates must be ubiquitinated before being degraded, there is 
some exclusion to this general rule, especially when the proteasome plays a normal role 
in post-translational processing (Young GW et al., 2008). The proteasomal activation of 
nuclear factor-kappa beta (NF-kβ) by processing p105 into p50 via internal proteolysis 
and degradation of the enzyme ornithine decarboxylase are two major examples (Young 
GW et al., 2008). With this background in mind, it is important – in the context of this 
thesis - to discuss the role of proteasome inhibitors as it is the main focus of this project, 
particularly as novel cardioprotective agents. 
1.17 Proteasome inhibitors 
Many different PIs have been described over the past decades, including those derived 
from natural sources and through organic synthesis. Both covalent reversible, covalent 
irreversible and non-covalent inhibitors have been described and employed. There are 
five different classes of covalent inhibitors, i.e. 1) peptide aldehydes 2) epoxyketones 3) 
boranic acids 4) vinyl sulfones 5) β-lactones (Beck P et al., 2012; Kisselev AF et al., 
2012). However, for the purposes of this thesis we will be focusing on peptide aldehydes 
(MG-132) and β–lactones (lactacystin).  
1.17.1 Peptide aldehydes 
The first class are the peptide aldehydes, with MG-132 (Z-Leu-Leu-Leucinal-) as its 
most widely used member (Rentsch A et al., 2013). Aldehydes form covalent, reversible 
bonds within the proteasome active sites and inactivate the catalytic activities by 
hemiacetal formation with the N-terminal threonine of the proteasome subunits (Rentsch 
A et al., 2013).  
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1.17.2 Epoxyketones 
A well-known class belongs to the epoxyketones family, with epomoxcin the most 
recognized. They are highly selective for the proteasome, and no other off targets have 
been found. They form active sites between threonine and epoxketone in which both the 
y-hydroxl and the free amine of the n-terminal threonine participate (Groll M et al., 
2000).  
1.17.3 Boranic acids 
The next class are the boranic acids, with bortezomib as the most renowned example. It 
forms tetrahedrals adducts with active site threonines, which are stabilised by hydrogen 
bonds. Bortezomib has been approved for the treatment of multiple myeloma patients 
(Groll M et al., 2006). 
1.17.4 Vinyl sulfones 
Vinyl sulfones are more readily synthesized and have been used in may peptide inhibitors 
and activity base probes. It can form covalent adducts by conjugate addition of the 
hydroxyl-group of the active site threonine (Groll M et al., 2002). 
1.17.5 β-lactones 
The last class are β-lactones, which form covalent and stable adducts to the proteasome 
by the attack of the catalytic threonine to lactone, thereby forming an ester bond. The 
most used form of this class is lactacystin (Groll M et al., 2006) that is a microbial 
natural product that inhibits cell proliferation and induces neurite outgrowth in a murine 
neuroblastoma cell line.  It has become a widely used reagent in functional studies of the 
proteasome. This small molecule is currently the only known compound that specifically 
inhibits the proteasome without blunting other proteases thus far tested in vitro.  It also 
does not inhibit intracellular lysosomal protein degradation in contrast to other commonly 
used proteasome inhibitors, such as peptide aldehydes and 3, 4-dichloroisocoumarin, 
which inhibit a wide range of proteases. Furthermore, it has chymotrypsin-like and 
trypsin-like activity. Lactacystin enters cells and inhibits the β5 subunit of the 20 
proteasome core, as a β-lactone derivative. Recently, a novel, small molecular-weight 
analog of lactacystin, clasto-lactacystin b-lactone (called PS519), was synthesized and 
shown to elicit cardioprotective effects following ischemia/reperfusion in isolated 
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perfused rat hearts (Pye et al., 2003) and to exhibit cerebroprotective properties in a rat 
model of focal cerebral ischemia. Lactacystin also has the ability to inhibit the system’s 
functionality more rapidly and without resulting in a stress response. Its use is highly 
portable, even to systems that are less tractable to molecular biology, such as tissues and 
multicellular organisms. 
The effects of PI during myocardial ischemia on cardiac function have been controversial, 
with both advantageous and damaging effects described.  However, short-term (acute) PI 
under certain conditions has shown early promise as a novel therapeutic approach for 
myocardial ischemia and reperfusion. Several mechanisms involved in cardioprotection 
by proteasome inhibition have been suggested, including inhibition of NF-kB 
inflammatory pathway activation, prevention of ventricular tachyarrhythmia inactivation 
of G-protein-coupled receptor kinase 2 (GRK2) and inhibition of cardiomyocyte 
apoptosis (Pye et al., 2003). 
1.18 Proteasomal involvement during myocardial ischemia and 
reperfusion 
Myocardial infarction results from irreversible myocardial necrosis caused by extensive 
ischemia and hypoxia. Early restoration of blood flow during myocardial ischemia is 
crucial for recovering the myocardium; unfortunately reperfusion itself can paradoxically 
intensify myocardial damage, this is known as reperfusion injury. Reperfusion injury 
involves the production of ROS, intracellular Ca
2+
 overload, microvascular and 
endothelial dysfunction, altered myocardial metabolism, activation of neutrophils, 
platelets, and complement (Hedhli N et al., 2007). Current research of the proteasome 
pathway in animal models of myocardial ischemia suggests that compromised proteasome 
function is linked with the pathophysiology of myocardial I/R. Proof for proteasome 
dysfunction has been established in various models by measurements of the build-up of 
ubiquitinated proteins and/or by demonstrating altered proteasome activity. These 
irregularities in proteasome function and changes within UPS components have been 
observed to variable degrees with myocardial ischemia (Table 2) (Yu X and Kem DC, 
2010). For example, CHIP-deficient mice are more inclined to I/R injury and exhibit an 
increase of reperfusion arrhythmias and increased infarct size compared to wild-type 
controls (Zhang C et al., 2005). This therefore provides evidence for the cardioprotective 
function of CHIP, with the mechanism CHIP’s ability to bind to damaged proteins with 
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molecular chaperone heat shock protein 70 (Hsp70) or Hsp90, to direct their re-folding or 
facilitate their degradation through ubiquitination (Zhang C et al., 2005). Likewise, 
hearts with reduced MDM2 (genetic mouse model) were more sensitive to I/Rinjury, 
while overexpression of MDM2 protected it against hypoxia/reoxygenation-induced 
apoptosis (Toth A et al, 2006). Therefore, MDM2 is believed to be a pre-requisite for 
conserving myocardial function and survival with I/R injury. MDM2 is also a key 
regulator of the pro-apoptotic transcription factor p53. It is responsible for p53 
ubiquitination and proteasome degradation, thus triggering cardioprotective effects as a 
result of the inhibition of p53-induced apoptosis (Toth A et al., 2006).  In addition, mice 
deficient in MuRF3 are pre-disposed to cardiac rupture after acute MI and this modulator 
is therefore vital for conservation of ventricular integrity and function after myocardial 
infarction. Moreover, Foo et al., (2008) established that oxidative stress-induced 
apoptosis was linked with decreased ARC (apoptosis repressor with caspase recruitment 
domain) and similar to the up-regulation of MDM2. Thus MDM2 endorses ARC protein 
turnover via ubiquitination and proteasome dependent degradation. Loss of ARC 
increased myocardial infarct size following ischemia/reperfusion (Foo RS et al., 2008), 
thus MDM2-mediated loss of ARC can increase cardiac damage. 
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Table 1.2 Regulation of the cardiac UPS in myocardial ischemia 
Experimental model UPS alterations References 
Rat model of myocardial I/R Increased ubiquitinated proteins; decreased 
20S proteasome activities; oxidative 
modification of 20S subunits 
Bulteau et al.  
I/R in isolated perfused rat heart Increased ubiquitinated proteins; decreased 
20S/26S proteasome activities 
Powell et al.  
I/R in isolated perfused rat heart Decreased 20S/26S proteasome activities Das et al. 
I/R in isolated perfused rat heart Selective inhibition of proteasome activity Gurusamy 
et al.  
Dog model of myocardial I/R Increased ubiquitinated proteins; decreased 
26S proteasome activities 
 Asai et al  
Rat model of chronic myocardial 
infarction 
Increased ubiquitinated proteins; increased E3 
ligase (MuRF 1/MAFbx) 
Adams et al  
Mouse model of chronic 
myocardial infarction 
Increased proteasome activity; increased 
11S/19S/20S subunits 
Hedhli et al.  
Rat H9c2 cardiomyocytes 
exposed to oxidative stress 
Increased E3 ligase (MDM2) Foo et al.  
Table 1.2, ischemia/reperfusion; MuRF-1, muscle ring finger 1; MAFbx, atrogin-1/muscle atrophy 
F-box; MDM2, murine double minute 2 adapted from Yu and Kem, 2010 
1.19 UPS and inflammation - hyperglycemia and I/R 
The most significant link between the UPS and inflammation is the transcription factor 
NFkβ that triggers expression of inflammation-associated target genes (Evans JL et al., 
2002). The proteasome is necessary for activation of NFkβ a vital transcription factor that 
controls inflammatory genes by degradation of its inhibitory Ikβ proteins (Karin M and 
Delhase M., 2000). NFkβ activation also leads to the expression of various cell survival- 
and proliferation-related genes (Evans JL et al., 2002). Latest findings propose that 
proinflammatory cytokines (PIC), like TNF-α, interleukin-1 beta (IL-1b) and IL-6, play 
central roles in the pathophysiology of heart disease (Sriramula S et al., 2008; Kang 
YM et al., 2008). Diabetes is usually associated with a chronic inflammatory state and 
animals with diabetes display increased NF-kβ p50 gene expression and NF-kβ p65 
activity (Mariappan N et al., 2010). Furthermore, chronic TNF-α administration induces 
cardiac damage and mitochondrial dysfunction (Mariappan N et al., 2010). NF-kβ p50 is 
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also amplified within mitochondria of obese db/db mice and has been linked with 
increased oxidative stress. Blockade of NF-kβ in obese mice led to protection of such 
hearts against oxidative stress, restored mitochondrial integrity, and improved cardiac 
function (Mariappan N et al., 2010). Moreover, genes which are controlled by NFkβ e.g. 
the IAP proteins, includes c-IAP1, c-IAP2, and XIAP. IAPs have been recognized as 
ubiquitin ligases, facilitating functional modification and degradation of effector 
molecules in apoptotic cells such as caspase-3 (Yang Y et al., 2000). The UPS is also 
involved in negatively regulating the pro-apoptotic transcription factor p53 (Yang Y et 
al., 2000). MDM-2 facilitates the relocation of p53 out of the nucleus and endorses the 
ubiquitination and degradation of p53. Auto-Ub of IAPs and their succeeding degradation 
by the proteasome is essential for apoptosis, as it eliminates their potent inhibitory impact 
upon caspases and therefore the advancement of cell death (Yang Y et al., 2000). 
Atherosclerosis is initiated as an inflammatory-proliferative reaction to an injurious 
stimulus, established by cardiovascular risk factors such as hypercholesterolemia, 
hypertension, smoking, diabetes, and age. Here endogenous oxidative stress causes 
modification of lipids, proteins, and DNA (Ames BN et al., 1993), leading to structural 
and functional alterations within the vascular wall. Furthermore, the reduction in 
bioavailability of NO as a result of increased assembly of ROS is another important 
pathophysiologic element in atherogenesis (Palombella VJ et al., 1944). Under normal 
conditions NO is produced by endothelial cells antagonizing pro-atherosclerotic processes 
and suppressing NFkB transcriptional activity, a pivotal mediator of the inflammatory-
proliferative process of atherogenesis. Decreased NO bioavailability together with an 
alteration of intracellular signaling pathways (due to increased  oxidative stress) 
subsequently leads to the initiation of the NFkB cascade (Palombella VJ et al., 1944) 
(Figure 1.8). 
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Figure 1.8 Model of NF-kB activation by hyperglycemia.  NFkB (nucleur factor kappa 
beta), Ikβα (interleukin kappa beta alpha), FFA (free fatty acids) modified from Evans et 
al, 2002 
 
Depending on PI class and experimental systems employed, the role of the UPS with 
hyperglycemia is contentious and it remains unclear whether decreased/increased activity 
is advantageous or not. For example, some studies found that with PIs, a beneficial effect 
was found (Marfella R et al., 2009; Powell SR et al., 2008), while others observed the 
converse, i.e. triggering damaging effects on the heart (Tsukamoto O et al., 2010; 
Tsukamoto S and Yokosawa H., 2009). For example, the 26S ATP-dependent activity 
reduced in response to prolonged hyperglycemia, while the 11S activity increased 
together with higher oxidative stress and impaired cardiac function (Powell SR and 
Divald A., 2010). This shows that increased 11S activity may be a compensatory 
mechanism to reduce the effects of oxidative stress in response to chronic hyperglycemia. 
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Moreover, others found that an elevated level of ubiquitinated proteins indicates a 
dysfunctional UPS (Powell SR and Divald A., 2010; Powell SR et al., 2008). 
These discrepancies in the activity of the UPS may arise from differences in the type and 
period of ischemia, the nature of the proteasome assays, the specificity and 
dosage/frequency of proteasome inhibitors, and the experimental model (cultured 
cardiomyocytes, ex vivo or in vivo heart models) used in different studies. A firm 
distinction must be made between studies using cultured cardiomyocytes, ex vivo 
(Langendorff with buffered perfusate) and in vivo heart models where the full 
complement of circulating metabolites and hormones are available.  
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1.20 Conclusion 
Although the elucidation of the UPS is still in its infancy in terms of its role in cardiac 
disease, there is some evidence suggesting its use as a therapeutic strategy in the case of 
diabetes/hyperglycemia presenting together with myocardial ischemia and reperfusion. It 
is known that hyperglycemia increases ROS, and that altered metabolic factors present 
during diabetes can cause glycation, oxidation, and cross-linking of proteins thereby 
altering proteasome function. An in-depth study on proteasome alterations in 
diabetic/hyperglycemic hearts has not been reported, however, increased proteasome 
function has been implicated in diabetes. Increased ROS may alter proteasome function 
through oxidative modification of the structural subunits. Despite such progress, the role 
of proteasome dysfunction with hyperglycemia/ diabetic cardiovascular disease remains 
to be fully determined and understood. As such this study focused on investigating 
proteasome inhibitors as novel cardioprotective agents that may blunt hyperglycemia-
induced contractile dysfunction during ischemic-reperfusion. The main aims of this thesis 
were to: 
1. Assess heart function (functional recovery and infarct sizes) ex vivo of rat hearts in 
response to ischemia-reperfusion under low and high glucose exposure with or without 
UPS inhibitors. 
2. Investigate the role of UPS inhibitors in hyperglycemia-mediated cardiac dysfunction 
with or without UPS inhibitors. 
3. Determine the role of oxidative stress in hyperglycemia-mediated cardiac dysfunction 
with or without UPS inhibitors. 
4. Determine the role of inflammation in hyperglycemia-mediated cardiac dysfunction with 
or without UPS inhibitors. 
5. Evaluate the overall status of candidate apoptotic signaling proteins under hyperglycemic 
conditions with or without UPS inhibitors. 
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Chapter 2 
Methods and Materials 
This chapter describes the methods that were carried out to pursue the hypothesis and 
aims described previously. The methods are divided into three sections i.e. ex vivo 
perfusions; Western blotting and the assessment of UPS activity. 
2.1 Animals and ethics statement 
All animals were treated in accordance with the Guide for the Care and use of Laboratory 
Animals of the National Academy of Sciences (NIH publication No. 85-23, revised 
1996). Studies were performed with the approval of the Animal Ethics Committee of 
Stellenbosch University (refer Appendix 1). Male Wistar rats (180-220 g) were used 
throughout the study and were allowed to acclimatize for a day at Stellenbosch 
University, after the arrival from the Tygerberg Campus. They were allowed access to 
food and water ad libitum. A standard light/dark cycle (12h - 12h) was employed.   
2.2 Drugs and chemicals used 
All reagents used were of analytical grade and these include: NaCl, KCl, MgSO4.7H2O, 
CaCl2.2H2O, KH2PO4 and NaHCO3. The drugs used in the perfusions were from Sigma 
Aldrich (St.  Louis, MO, USA) and included: Lactacystin, MG132 (Z-Leu-Leu-Leu-al), 
Ibuprofen sodium salt (referred to as ibuprofen in this thesis) and N- acetylcystine (NAC). 
2.3 Ex-vivo perfusions global ischemia during simulated acute 
hyperglycemia 
 
In our initial experiments we evaluated the effects of MG132. To validate our findings we 
further investigated whether lactacystin elicited the same effects on the rat heart under 
high glucose conditions following ischemia and reperfusion. Rats were anesthetized 
(pentobarbitone, 100 mg/kg i.p) and hearts rapidly excised and perfused in a modified 
Langendorff model with Krebs-Henseleit buffer (refer Appendix 2 for preparation) 
equilibrated with 95% O2-5% CO2 (37°C, pH 7.4) at a constant pressure (100 cm). The 
Krebs-Henseleit buffer contained (in mM) 11 Glucose, 118 NaCl, 4.7 KCl, 1.2 
MgSO4.7H2O, 2.5 CaCl2.2H2O, 1.2 KH2PO4, and 25 NaHCO3. Hearts were randomly 
distributed into the following experimental groups:  
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Table 2.1 Investigational heart grouping 
 
 
The Krebs-Henseleit buffer mimics the key ionic content of rat plasma or blood (Hearse 
D and Sutherland F., 2000;  Skrypiec-Spring M et al., 2007) and led to no 
hemodynamic dysfunction in the ex vivo heart perfusion system (Cunningham MJ et al 
., 1990). The use of the high glucose perfusions, attempts to simulate acute 
hyperglycemia within the clinical setting. Moreover, since ex vivo Langendorff perfusions 
are typically performed with 11 mM glucose at baseline, we are of the opinion that the 33 
mM concentration is representative of a three-fold elevation of glucose levels (above 
normal) within the clinical setting. 
The protocol was divided into two parts, i.e. perfusions a) with global ischemia and b) 
regional ischemia followed by reperfusion for cardiac functional assessment and infarct 
size determination, respectively.  Various drugs were employed for this study: the effect 
of UPS inhibition, (5 μM lactacystin, 10 μM MG132), the role of inflammation (29 μM 
Ibuprofen), and the role of oxidative stress (0.4 mM NAC) was administered during the 
first 20 min of reperfusion (Figure 2.1A). Lactacystin and MG132 were directly dissolved 
in the buffer; however, ibuprofen was initially heated in deionized water (Ghorab MK 
and Adeyeye MC., 2003) and NAC in 100% ethanol (Llu Y et al., 2007). Less than 
0.0005% (v/v) DMSO and 0.001% (v/v) ethanol was present during perfusion 
experiments.  The doses used for these drugs were based on perfusion studies (Yew et al., 
2005; Meiners S et al., 2002; Use of NSAID for Relief of Pain in Rodents and 
Rabbits” Lab Animal 26: p. 241-255; Peng Y et al., 2011). 
11 mM glucose n= 8/group 33 mM (High) glucose n= 8/group 
Untreated Untreated 
5 µM Lactacystin (treated) 5 µM Lactacystin (treated) 
10  µM MG132 (treated) 10  µM MG132 (treated) 
29 µM Ibuprofen (treated) 29 µM Ibuprofen (treated) 
0.4 mM NAC (treated) 0.4 mM NAC (treated) 
NAC + Ibuprofen (treated) NAC + Ibuprofen (treated) 
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Figure 2.1 Schematic diagrams showing the perfusion protocols for evaluation of the effects of 
various drug treatments (Lactacystin, MG132, Ibuprofen and NAC) on (A) heart contractile 
function following global ischemia and (B) infarct size following regional ischemia. 
During perfusion, a latex balloon attached to a pressure transducer (Stratham MLT 
0380/D, AD Instruments Inc., Bella Vista, NSW, Australia) compatible with the 
PowerLab System ML410/W (AD Instruments Inc., Bella Vista, NSW, Australia), was 
inserted into the left ventricle and inflated to produce a diastolic pressure of 4-12 mm Hg. 
The protocol included a 60 min stabilization period, 20 min of global ischemia, followed 
by reperfusion for 60 min. Contractile parameters assessed included heart rate (HR), left 
ventricular developed pressure (LVDP; LVDP = systolic pressure – diastolic pressure), 
and rate-pressure product (RPP; RPP = HR x LVDP). Coronary flow (CF) was measured 
by collection of the effluent at regular timed intervals. Both left and right ventricular 
tissues were collected after 60 min of reperfusion. Collected tissues were freeze-clamped 
in liquid nitrogen and stored at -80°C for further analysis. 
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2.4 Ex-vivo regional ischemia and reperfusion during simulated acute 
hyperglycemia 
 
To further strengthen our Langendorff functional data, we also evaluated the effects of 
Lactacystin and MG132 by infarct size determination. This was performed as described 
before but with slight modifications (Kelly RF et al., 2010), i.e. we employed regional 
ischemia with a reperfusion time of 2 hr. (see Figure 2.1B). Here a 3/0 silk suture was 
placed on the proximal portion of the left anterior descending coronary artery and passing 
the ends through a plastic tube. For induction of regional ischemia, the ends were 
tightened by pressing the plastic tube against the surface of the heart (above the artery) 
for 20 min. The snare was released during the reperfusion period. The efficacy of 
ischemia was confirmed by regional cyanosis and a substantial decrease in coronary flow 
as well as in LVDP. 
2.5 Determination of infarct size 
After completion of each regional ischemia and reperfusion experiment the snare was re-
tightened and 2.5% Evans Blue dye (in Krebs buffer) was perfused through the hearts for 
infarct development. Hearts were subsequently removed from the Langendorff apparatus, 
blotted dry, suspended within 50 ml plastic tubes (using suture) and frozen at -20°C for 3 
days. Thereafter, frozen hearts were sliced into 2 mm transverse sections and incubated 
with 1% 2,3,5-triphenyl tetrazolium chloride (TTC) in phosphate-buffered saline for 20 
min at 37°C to identify non-infarcted (stained) from infarcted (nonstained) tissues. The 
area that was not stained with Evans Blue was defined as the area at risk (AAR). The area 
which demonstrated neither blue nor red was defined as the infarct site. Slices were then 
fixed in 10% formalin for 24 hr at room temperature before being placed between glass 
plates for scanning (both sides). The infarct area (IA) size and the area at risk (AAR) 
were calculated using Image J software (v1.46p, National Institutes of Health, USA) (see 
Appendices 3 and 4). Values of tissue slices were added together in order to obtain the 
total IA and AAR for each heart analyzed. We expressed the infarct size as the ratio of IA 
versus the AAR (%IA/AAR) [see appendix 3 and 4]. Coronary flow was decreased by 
40% ± 3.9 under control conditions and 35% ± 2.6 under hyperglycemic conditions this 
was together seen with a drop in LVDP by 5mm/hg respectively thereby proving ligation 
consitancy. 
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2.6 Western blot analysis 
Protein isolation was performed as previously described in our laboratory (Rajamani U 
and Essop MF., 2010). Briefly, collected heart tissues were homogenized with modified 
RIPA buffer (see Appendix 5); the supernatant was centrifuged twice at 4, 300 g for 10 
min at 4°C then stored at -80°C until further use. Protein concentration was determined 
by employing the Bradford technique, with BSA as the protein standard (see Appendix 
5). 
Samples for Western blotting were prepared by addition of a Laemmli sample buffer 
containing β-mercaptoethanol to a final protein concentration of 50 μg. Samples were 
boiled at 95°C to ensure denaturation of proteins into a linear formation, capable of 
migrating through the SDS-PAGE gel. Briefly, prepared samples were then loaded in 
commercially available 10-well precast Mini-PROTEAN® TGX Stain-Free™ 
polyalcrylamide gels (Bio-Rad, Hercules CA, USA) and subjected to electrophoresis in a 
1× running buffer containing 25 mM Tris, 192 mM glycine, 0.1% SDS, and at pH 8.3.  
Gels were electrophoresed at 250 V until adequate separation of proteins was achieved. 
Hereafter transfer of proteins from the gel to the membrane was performed by the 
employment of commercially available transfer packs in conjunction with the Trans-
Blot® Turbo™ Transfer system (Bio-Rad, Hercules CA, USA). The system makes use of 
semi-dry transfer, ensuring the migration of separated proteins from the gel to the pre-wet 
polyvinylidene fluoride (PVDF) membrane contained in the transfer pack, in 7 min (see 
Appendix 6). The membrane was then subjected to various washing steps in Tris-
buffered saline solution containing Tween-20 (2 L TBS-T: 20 mM Tris-HCl, 500 mM 
NaCl, 2 mL Tween-20). Blocking for the primary antibody was performed using 5% fat-
free milk solution (5 g fat-free dry milk powder dissolved in 100 mL TBS-T solution). 
The membrane was incubated to settle with the primary antibody (1:1,000) at 4°C, 
overnight (Table 1) Incubation in secondary antibody, 1:4,000 or 1:10,000 concentrations, 
was performed at room temperature (see Appendix 7). 
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Table 2.2 Antibodies employed for Western blotting analysis 
 Primary antibody Supplier 
Cell death 
ARC α-rabbit ARC Sigma-Aldrich, MO, USA 
PARP α-rabbit PARP Cell Signaling Technology, MA, USA 
Total Bad α-rabbit Bad Santa Cruz Biotechnologies, CA, USA 
Bcl-2 α-rabbit Bcl-2 Santa Cruz Biotechnologies, CA, USA 
Caspase-3 α-rabbit Caspase-3 Cell Signaling Technology, MA, USA 
Cytochrome C α-rabbit 
Cytochrome C 
Cell Signaling Technology, MA, USA 
pBad α-rabbit pBad Santa Cruz Biotechnologies, CA, USA 
Inflammation 
IkB-α α-rabbit IkB-α Sigma-Aldrich, MU, GER 
TNF-α α-rabbit TNF-α Sigma-Aldrich, MU, GER 
IL-6 α-rabbit IL-6 Cell Signaling Technology, MA, USA 
ROS 
eNOS α-rabbit eNOS Santa Cruz Biotechnologies, CA, USA 
Sod1 α-rabbit Sod1 Santa Cruz Biotechnologies, CA, USA 
Sod2 α-rabbit Sod2 Santa Cruz Biotechnologies, CA, USA 
Autophagy 
P62 α-rabbit P62 Cell Signaling Technology, MA, USA 
LC3 I/II α-rabbit LC3 II Cell Signaling Technology, MA, USA 
Others 
GR2K α-rabbit GR2K Sigma-Aldrich, MU, GER 
Ubiquitin α-rabbit Ubiquitin Cell Signaling Technology, MA, USA 
β -actin α-rabbit β -actin Cell Signaling Technology, MA, USA 
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Visualization of the membrane was performed with enhanced chemiluminescence (ECL). 
Briefly, as a result of the conversion of luminol to 3-aminophtalae, catalyzed by the 
horseradish peroxidase (HRP) enzyme linked to secondary antibody, light emission at 428 
nm is detected via a digital camera by the ChemiDoc™ XRS+ system with Image Lab™ 
Software v2.0 (Bio-Rad, Hercules CA, USA) and a digital image is produced on a 
computer.  
Protein expression was determined by the adjusted percentage volume, (intensity units of 
pixels of band × mm2), after background subtraction (Quantity One Software v4.6.9, 
BioRad, Hercules CA, USA), and normalized to β-actin to correct for loading variations. 
The adjusted volume for the control group was represented as 100%, and corresponding 
values for vehicle and treatment groups were expressed as a percentage of the average of 
the control. This method was performed for each experiment separately before all values 
were combined in the statistical program. An n=8 was used for each experimental group. 
2.7 Proteasome activity measurements 
Proteasome activity measurements Chymotrypsin-like, trypsin-like, and caspase-like 
activities of the proteasome were assayed using fluorogenic peptides (Sigma-Aldrich, St 
Louis, MO, USA): Suc-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (LLVY-MCA at 25 
μM), N-t-Boc-Leu-Ser-Thr-Arg-7-amido-4-methylcoumarin (LSTR MCA at 40 μM) and 
N-Cbz-Leu-Leu-Glu-b-naphthylamide (LLE-NA at 150 μM), respectively (28). Assays 
were performed with ~50 μg of protein lysate (in 25 mM Tris–HCl, pH 7.5) and the 
appropriate substrate that were incubated together for 0-30 min at 37°C. 
Aminomethylcoumarin and β-naphthylamine fluorescence were measured at 
excitation/emission wavelengths of 350/440 and 333/410 nm, respectively, using a 
Fluostar fluorometric microplate reader (BMG Labtech, Ortenberg, Germany). Peptidase 
activities were measured in the absence/presence of 20 μM of the proteasome inhibitor, 
MG-132 (N-Cbz-Leu-Leu-leucinal), and the difference between the two values was 
attributed to proteasome activity. Data were normalized to protein concentrations. 
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2.8 Glutathione assay Kit 
Glutathione (GSH) was measured using the glutathione assay kit (Sigma-Aldrich, St 
Louis, MO, USA) in heart tissue extracts. The samples were first deproteinized with 5% 
5-sulfosalicylic acid solution. Glutathione content of the sample was then assayed using a 
kinetic assay in which catalytic amounts of glutathione cause a continuous reduction of 5, 
5’-dithiosbis-(2-nitrobezoic) acid (DTBN) to TBN. Oxidized glutathione is formed and 
recycled by glutathione reductase and NADPH. TBN is assayed colorimetrically at 
421nm. 
2.9 Statistical analysis 
Data are presented as mean ± standard error of mean (SEM). Differences between 
treatment groups and time points were analyzed using one way analysis of variance 
(ANOVA) followed by Tukey –Kramer post hoc. Mann-Whitney unpaired t-test was used 
when comparisons were made between only two groups. All statistical analyses were 
performed using GraphPad Prism version 5.01 (Graphpad Software, Inc, San Diego, 
USA). Values were considered significant when p<0.05. 
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Chapter 3: Results 
 
Diabetes represents a foremost health challenge, which causes cardiovascular 
complications thus further increasing the overall burden of the disease. Moreover, stress-
induced hyperglycemia in non-diabetic individuals with AMI is linked with higher in-
hospital mortality. Prior studies associate oxidative stress, inflammation and a 
dysfunctional UPS as potential mediators of this process. Thus far, PIs such as lactacystin 
and MG-132 have yielded mixed results but with the promise of offering potential 
benefits as novel therapeutic interventions in this case. However, additional studies are 
required to determine the mechanisms underlying dysfunctional UPS in the heart under 
hyperglycemic conditions. We therefore hypothesized that PIs reduce acute 
hyperglycemia-mediated pathophysiologic molecular events such as, oxidative stress, 
apoptosis, inflammation, UPS, and thereby improve contractile function in response to 
I/R. 
 
3.1 Evaluation of ex vivo heart function during global ischemia and 
reperfusion (simulated acute hyperglycemia) ± MG-132 
 
Our results indicate that acute hyperglycemia during the onset of I/R elicits detrimental 
effects on the heart as shown by both the reduced LVDP (Figure 3.1A, p<0.01 vs. 
control) and RPP recovery (Figure 3.1B, p<0.05 vs. control). LVDP improved to 26 ± 
3.9% for control hearts whereas high glucose perfused hearts recovered to only 12.3 ± 
2.6% after 60 min of reperfusion. Similarly RPP recovery improved in control hearts after 
60 min of reperfusion versus hyperglycemic hearts (Figure 3.1B, 25.5 ± 1.7% vs. 13.0 ± 
1.6%, p<0.05). 
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Figure 3.1 High glucose-induced cardiac contractile dysfunction in rat hearts exposed to 
high glucose conditions vs. baseline glucose concentrations. Isolated rat hearts were perfused 
under high glucose conditions (33 mM glucose) vs. controls (11 mM glucose) for 60 min and 
subjected to 20 min of global ischemia, followed by 60 min of reperfusion. (A) Left ventricular 
developed pressure (% recovery) and (B) rate pressure product (RPP) (% recovery) between 
control and high glucose perfused groups. Values are expressed as mean ± SEM (n=8). *p<0.05, 
**p<0.01 vs. respective controls. 
 
To test our hypothesis, we next performed similar experiments but in the presence of 
MG-132, a specific UPS inhibitor. Our findings show that acute MG-132 treatment (20 
min) significantly improved LVDP at baseline (11 mM glucose) and for the high glucose 
group (Figures 3.2A and B). Changes in rate pressure product (RPP) reflected a similar 
trend (Figures 3.2C and 3.2D), while no differences were found for the HR and dP/dt max 
(Figure 3.3). 
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Figure 3.2 Acute MG-132 treatment increases cardiac contractile function under baseline 
glucose and high glucose perfusion conditions reflected by improved LVDP and RPP vs. 
untreated hearts. Isolated rat hearts were perfused under simulated hyperglycemic conditions 
(33 mM glucose) vs. controls (11 mM glucose) and subjected to 20 min of global ischemia, 
followed by 60 min of reperfusion. 10 μM MG-132 were added to the treatment group during the 
first 20 min of reperfusion. (A) Left ventricular developed pressure (% recovery) at baseline 
glucose levels (11 mM), and (B) with high glucose (33 mM). Rate pressure product (RPP) at 
baseline glucose levels (C), and (D) under high glucose conditions. Values are expressed as mean 
± SEM (n=8). ***p<0.001 vs. respective controls. 
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Figure 3.3 MG-132 treatments had no effect on HR and dP/dt max. Isolated rat hearts were 
perfused under simulated hyperglycemic conditions (33 mM glucose) vs. controls (11 mM 
glucose) and subjected to 20 min of global ischemia, followed by 60 min of reperfusion. 10 μM 
MG-132 were added to the treatment group during the first 20 min of reperfusion. (A) Heart rate 
(HR) at baseline glucose levels (11 mM), and (B) with high glucose (33 mM). Velocity of 
contraction (dP/dt max) at baseline glucose levels (C), and (D) under high glucose conditions. 
Values are expressed as mean ± SEM (n=8). 
 
Additionally, MG-132 treatment enhanced coronary flow vs. untreated group 
significantly (p<0.05) under high glucose perfusion condition (Table 3.1). This was 
accompanied by a decrease in end diastolic pressure in hearts exposed to high glucose 
conditions though there were no changes in the control group. 
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Table 3.1. Coronary flow and end-diastolic pressure (EDP) under high glucose vs. baseline 
(11 mM) glucose conditions during the first ten min of stabilization (“Pre-ischemia”) and at 
the end of reperfusion (“Post-ischemia”). 
 
 Coronary Flow (ml/min) EDP (mmHg) 
Pre-
ischemia 
(1
st
 10min) 
Post-
ischemia 
(140min) 
Pre-
ischemia 
Post-
ischemia 
Control (11 mM) 10 ± 2.3 8.2 ± 1.3 14 ± 0 33 ± 5 
10  µM MG-132 12 ± 1 8 ± 2.4 11 ± 2 31 ± 2 
High Glucose  
    (33 mM) 
11.2 ± 1.8 6 ± 1.5 8 ± 3 65 ± 7* 
10  µM MG-132 7 ± 1 11 ± 1* 14 ± 2 22 ± 5* 
 
Values are expressed as mean ± SEM. *p<0.05vs. respective control, (n=8 per group). 
3.2 Assessment of infarct size following regional ischemia and reperfusion 
(simulated acute hyperglycemia ± MG-132) 
 
We next proceeded to strengthen our findings by testing the effects of MG-132 on infarct 
size following regional ischemia. The data demonstrate that the infarct size was 
noticeably higher in the high glucose compared to the control group (Figure 3.4). 
However, MG-132 treatment decreased infarct sizes following regional ischemia at 
baseline (11 mM glucose) and under high glucose conditions (Figure 3.4A),  diminishing 
infarct sizes to 40.3 ± 2.5% (11 mM) and 49.7 ± 7.4% (33 mM) versus 56.3 ± 2.8% (11 
mM) and 73.5 ± 4.9% (33 mM) at baseline and high glucose perfusions, respectively. 
There were no differences in the area at risk amongst all the groups (Figure 3.4B). 
 
 
 
 
 
 
Stellenbosch University  https://scholar.sun.ac.za
55 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 MG-132 administration exhibited cardio-protective properties following regional 
I/R under high glucose perfusion conditions. Isolated rat hearts were perfused under high 
glucose conditions (33 mM) vs. controls (11 mM) and subjected to regional ischemia. For MG-
132 treated groups, 10 μM MG-132 was given during the first 20 min of the two hour reperfusion 
period. (A) Infarct size/area at risk (%) and (B) area at risk under baseline (simulated 
normoglycemia) vs. high glucose perfusion conditions (simulated acute hyperglycemia). Evans 
blue dye and TTC staining allowed visualization of viable tissue (blue), infarcted area (white) and 
the area at risk (red). Values are expressed as mean ± SEM (n=8). **p<0.01, ***p<0.001 vs. 
respective controls. 
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3.3 The effects of MG-132 treatment on myocardial proteasomal activity in 
hearts exposed to ischemia and reperfusion under high glucose settings 
 
We subsequently assessed post-ischemic proteasomal activity in our experimental system. 
These data revealed that hyperglycemia induced a marked increase in chymotrypsin-like, 
trypsin-like proteasomal activity following I/R (Figure 3.5). The 11 mM glucose 
perfusions MG-132 treatment decreased chymotrypsin-like proteasomal activity 
compared to the untreated control significantly (p<0.01), but did not result in any 
significant effects on trypsin-like and caspase-like proteasomal activities (Figure 3.6B). 
Moreover, MG-132 treatment considerably reduced chymotrypsin-like proteasomal 
activities in high glucose exposed rat hearts (Figure 3.6B). Conversely, no effects were 
observed on caspase-like activity in such hearts (Figure 3.6C and 3.6D). Total 
ubiquitinated protein was unexpectedly decreased (Figure 3.6A). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5 Increased proteasomal activity in hearts subjected to I/R under high glucose 
conditions. Isolated rat hearts were perfused under high glucose conditions vs. controls and 
subjected to ischemia and reperfusion. A) Chymotrypsin-like proteasomal, (B) trypsin-like, and 
(C) caspase-like activities after 60 min of reperfusion under high glucose conditions (33 mM) vs. 
control (11 mM). Values are expressed as mean ± SEM (n=8). *p<0.05,*p<0.01 vs. respective 
controls. 
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Figure 3.6 MG-132 reduces high glucose-induced chymotrypsin-like proteasomal activity 
following I/R. Isolated rat hearts were perfused under high glucose (33 Mm) conditions vs. 
controls and subjected to I/R. For MG-132 treatment groups, 10 μM MG-132 was added during 
the first 20 min of reperfusion.(A) Total ubiquitinated proteins (B) chymotrypsin-like 
proteasomal, (C) trypsin-like, and (D) caspase-like activities after 60 min of reperfusion at 
baseline (11 mM glucose). Values are expressed as mean ± SEM (n=8). *p<0.05, **p<0.01, 
***p<0.001 vs. respective controls. 
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combination of NAC and Ibuprofen displayed an additive cardioprotective effect under 
high glucose conditions (Figures 3.7A and 3.7B p<0.001 and C/D p<0.01).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.7 NAC and Ibuprofen treatment elicit increased cardiac contractile function under 
baseline and high glucose conditions. Isolated rat hearts were perfused under simulated 
hyperglycemic conditions (33 mM glucose) vs. controls (11 mM glucose) and subjected to 20 min 
of global ischemia, followed by 60 min of reperfusion. We added a) 0.4 mM NAC, or b) 29 µM 
Ibuprofen, or c) NAC and Ibuprofen during the first 20 min of reperfusion. (A) Left ventricular 
developed pressure (% recovery) at baseline glucose levels (11 mM), and (B) with high glucose 
(33 mM). Rate pressure product (RPP) at baseline glucose levels (C), and (D) under high glucose 
conditions. Values are expressed as mean ± SEM (n=8). *p<0.05, **p<0.01, ***p<0.001 vs. 
respective controls. 
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Changes in coronary flow and end-diastolic pressure under baseline (11 mM) and with 
simulated hyperglycemia ± NAC and Ibuprofen concentrations are shown in Table 3.2. 
Ibuprofen treatment increased coronary flow vs. untreated group (p<0.05) under high 
glucose perfusion conditions. This was accompanied with a decrease in end diastolic 
pressure in hearts exposed to high glucose conditions (p<0.001) though there were no 
changes in the control group. The combination treatment group followed the same trend 
with significant changes found in coronary flow vs. untreated group (p<0.05) under high 
glucose conditions as well as a reduction in end diastolic pressure (p<0.001). However, 
no changes were observed in heart rate and dP/dt max in either groups of treatment 
following I/R. Infarct size however, was not measured for both Ibuprofen and NAC. 
Table 3.2 Coronary flow, end-diastolic pressure, heart rate and velocity of contraction for 
hearts perfused under high glucose (33 mM) vs. control (11 mM) ± NAC and Ibuprofen 
treatments as discussed. 
 
EDP- end diastolic pressure; dP/dt max - maximal velocity of contraction. 29  µM Ibuprofen (anti-
inflammatory); 0.4 nM NAC (antioxidant). Values are expressed as mean ± SEM. 
*p<0.05;**p<0.01 vs. respective control. (n=8 per group). Values shown at the end of reperfusion 
To sum up, the MG-132 yielded very promising data and to confirm such effects we 
performed additional experiments by employing lactacystin, a more potent and specific 
PI. 
 Coronary Flow 
(ml/min) 
EDP 
(mmHg) 
HR 
(beats/min) 
dP/dt max 
(mmHg/s) 
Control (11 
mM) 
8.2 ± 1.3 33 ± 5 282 ± 24 1112 ± 63 
0.4 mM NAC 6 ± 3 28 ± 3 326 ± 8 1062 ± 56 
29  µM 
Ibuprofen 
9 ± 1 31 ± 4 302 ± 14 1500 ± 16 
NAC + 
Ibuprofen 
6 ± 3 32 ± 1 274 ± 12 1333 ±78 
High Glucose 
(33 mM) 
6 ± 1.5 65 ± 7* 361 ± 18 1133 ± 45 
0.4 mM NAC 9 ± 1 48 ± 2 242 ± 12 1237 ± 47 
29  µM 
Ibuprofen 
12 ± 1.5 * 31 ± 4** 215 ± 30 1600 ± 33 
NAC + 
Ibuprofen 
11 ± 2* 29 ± 4** 243 ± 9 1000 ± 54 
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3.4 Evaluation of ex-vivo heart function during global ischemia and 
reperfusion (simulated acute hyperglycemia) ± lactacystin 
Lactacystin treatment improved functional recovery of the control and high glucose 
groups, i.e. to 36 ± 4% and 34 ± 2.3%, respectively (Figures 3.8A and 3.8B). Lactacystin 
treatment also improved RPP for the high glucose perfused group significantly but 
showed no significant effects for baseline treated hearts (Figures 3.8C and 3.8D), while 
dP/dt max (Figures 3.9A and 3.9B) and HR (Figure 3.9C and 3.9D) remained unaltered. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8 Lactacystin treatment during reperfusion improves contractile function at baseline 
and under high glucose condition following I/R. Isolated rat hearts were perfused under simulated 
hyperglycemic conditions (33 Mm glucose) vs. controls (11 mM glucose) and subjected to 20 min of 
global ischemia, followed by 60 min of reperfusion. 5 μM lactaystin were added to the treatment 
group during the first 20 min of reperfusion. (A) Left ventricular developed pressure (% recovery) at 
baseline glucose levels (11 mM), and (B) with high glucose (33 mM). Rate pressure product (RPP) at 
baseline glucose levels (C), and (D) under high glucose conditions. Values are expressed as mean ± 
SEM (n=8).*p<0.05, **p<0.01, ***p<0.001 vs. respective controls. 
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Figure 3.9 The effects of lactacystin treatment on HR and dP/dt max. Isolated rat hearts were 
perfused under simulated hyperglycemic conditions (33 mM glucose) vs. controls (11 mM glucose) 
and subjected to 20 min of global ischemia, followed by 60 min of reperfusion. 5 μM lactaystin were 
added to the treatment group during the first 20 min of reperfusion. (A) Heart rate (HR) at baseline 
glucose levels (11 mM), and (B) with high glucose (33 mM). Velocity of contraction (dP/dtmax) at 
baseline glucose levels (C), and (D) under high glucose conditions. Values are expressed as mean ± 
SEM (n=8). 
 
Lactacystin treatment also significantly improved coronary flow vs. untreated group under 
high glucose perfusion setting. This was accompanied by a reduction in end-diastolic 
pressure in hearts exposed to high glucose conditions, though there were no differences for 
the control group (Table 3.3). 
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Table 3.3. Effects of lactacystin on ex vivo coronary flow and end-diastolic pressure during 
the first ten min (‘Pre-ischemia’) of stabilization and at the conclusion of reperfusion (‘Post-
ischemia’). 
 
 
 Coronary Flow (ml/min) EDP (mmHg) 
Pre-
ischemia 
Post-
ischemia 
Pre-
ischemia 
Post-
ischemia 
Control (11 mM) 10 ± 2.3 8.2 ± 1.3 14 ± 0 33 ± 5 
5 µM Lactacystin 8.4 ± 1 7.5 ± 1.5 10 ± 1 29 ± 7 
High Glucose  
(33 mM) 
10.2 ± 1.8 6 ± 1.5 8 ± 3 65 ± 7* 
5 µM Lactacystin 9 ± 2 11.2 ± 0.6* 15 ± 3 26 ± 7** 
 
Values are expressed as mean ± SEM. *p<0.05; **p<0.01 vs. respective controls, (n=8 per 
group). 
 
3.5 Assessment of infarct size following regional ischemia and 
reperfusion (simulated acute hyperglycemia) ± lactacystin 
The regional I/R experiments demonstrated lactacystin treatment of high glucose perfused 
hearts attenuated the infarct size from 66.4 ± 3.4% to 48 ± 3.9% (p<0.05 vs. high glucose 
untreated) with no variations for the area at risk between the groups (Figure 3.10). 
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Figure 3.10 Lactacystin administration leads to cardio-protection following regional I/R. 
Isolated rat hearts were perfused under high glucose conditions (33 mM) vs. controls (11 mM) 
and subjected to regional ischemia. For lactacystin treated groups, 5 μM was given during the first 
20 min of the two hour reperfusion period. (A) Infarct size/area at risk (%) and (B) area at risk 
under baseline (simulated normoglycemia) vs. high glucose perfusion conditions (simulated acute 
hyperglycemia). Evans blue dye and TTC staining allowed vizualization of viable tissue (blue), 
infarcted area (white) and the area at risk (red). Values are expressed as mean ± SEM (n=8). 
*p<0.05, **p<0.01 vs. respectively controls. 
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3.6 Lactacystin treatment diminishes proteasomal activity 
 
Our data revealed that there was a significant reduction in post-ischemic chymotrypsin-
like activities under both low and high glucose conditions with the treatment of 
lactacystin (Figure 3.11B). However, there was no effect on post-ischemic trypsin and 
caspase-like proteasomal activity under baseline conditions or high glucose conditions 
(Figure 3.11C and 3.11D). General ubiquitinated proteins were lower with lactacystin 
under control and high glucose perfusion conditions (Figure 3.11A). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11 Lactacystin decreases high glucose-induced chymotrypsin-like proteasomal activity 
after I/R. Isolated rat hearts were perfused under high glucose (33 mM) conditions vs. controls and 
subjected to ischemia and reperfusion. For lactacystin treatment groups, 10 μM MG-132 was added 
during the first 20 min of reperfusion.(A) Total ubiquitinated proteins (B) chymotrypsin-like 
proteasomal, (C) trypsin-like, and (D) caspase-like activities after 60 min of reperfusion at baseline 
(11 mM glucose). Values are expressed as mean ± SEM (n=8). *p<0.05, **p<0.01, ***p<0.001 vs. 
respective controls. 
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3.7 Comparative analyses of treatment modalities 
Our data established that MG-132 treatment triggered robust cardio-protection at baseline 
and under high glucose, to a much greater extent than lactacystin (Figure 3.12). Ibuprofen 
provided the next best treatment option under high glucose conditions, followed by NAC 
(Figure 3.13). Infarct sizes were also attenuated by both treatments; however MG-132 
elicited a greater effect than lactacystin (Figure 3.14). Chymotrypsin-like proteasomal 
activities were lower with either PI with no effects found with trypsin and caspase-like 
proteasomal activity (Figure 3.15).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12 Comparative assessment of PI treatment during reperfusion improves function 
recovery at baseline and under high glucose conditions following I/R.  
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Figure 3.13 Comparison of treatment modalities with I/R under high glucose conditions. 
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Figure 3.14 Comparison infarct size percentage deceased for MG-132 vs. lactacystin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.15 Comparison of proteasomal activity between MG-132 vs. lactacystin. 
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For the remainder of this study we employed lactacystin as the PI of choice. This was 
done for several reasons: a) lactacystin is considered a more specific inhibitor of the UPS, 
while MG-132 may have additional, nonspecific outcomes. These include interaction with 
MAPK as well as JNK 1, which is activated during the hyperglycemia and may have 
direct or indirect effects on certain markers we are investigating. (Powell SR., 2006; 
Tsukamoto O et al., 2010; Zolk O et al., 2006), and b) assessment of one inhibition is 
more cost-effective approach in terms of resources available for this study. 
 
3.8 Effects of lactacystin treatment on myocardial ROS levels and apoptosis 
 
We next assessed whether lactacystin cardio-protection is associated with anti-oxidant 
and anti-apoptotic properties in heart tissues collected from our experimental system. 
Here acute hyperglycemia during the onset of I/R increased cleaved PARP (Figure 3.16A 
p<0.05 vs. untreated control) and this effect was blunted with lactacystin treatment 
(p<0.01 vs. untreated high glucose). Moreover, lactacystin treatment significantly 
enhanced SOD1 and SOD2 peptide levels under control and high glucose conditions vs. 
controls (Figure 3.16B p<0.05, p<0.001, Figure 3.16C p<0.01, p<0.001). The GSH was 
increased with lactacystin for the control group (Figure 3.16D p<0.05). Conversely, under 
high glucose conditions no change was found with treatment.   
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Figure 3.16 Anti-oxidant effects of lactacystin in hearts subjected to I/Runder baseline and 
high glucose conditions. Isolated rat hearts were perfused under high glucose conditions vs. 
controls and subjected to I/R ± lactacystin treatment during reperfusion. Western blot analysis for 
A) PARP; B) SOD1; C) SOD2 peptide levels is shown with β–actin as loading control; D) 
GSH/GSSG ratio . Values are expressed as mean and ± SEM (n=8). *p<0.05, **p<0.01, 
***p<0.001 vs. respective controls. 
 
In terms of apoptotic markers evaluated, lactacystin treatment reduced cleaved caspase-3 
and cytochrome c peptide levels under control and high glucose conditions (Figure 3.17A 
p<0.01 and 3.17B p<0.001). Anti-apoptotic markers such as p-BAD/BAD, Bcl-2 (Figure 
3.17C and 3.17D) and ARC (Figure 3.18) were diminished under high glucose conditions 
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(p<0.05, p<0.001, p<0.01 correspondingly) nonetheless this effect was reversed with 
lactacystin treatment under high glucose perfusion conditions. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.17 Anti-apoptotic effects of lactacystin in hearts subjected to I/R under high 
glucose conditions. Isolated rat hearts were perfused under high glucose conditions vs. controls 
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and subjected to ischemia and reperfusion ± lactacystin treatment during reperfusion. Western 
blot analysis for A) caspase- 3; B) cytochrome c; C) Bcl-2 and D) pBad/Bad peptide levels is 
shown with β–actin as loading control. Values are expressed as mean ± SEM (n=8). *p<0.05, 
**p<0.01, ***p<0.001 vs. respective controls. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.18 Anti-apoptotic effects of lactacystin in hearts subjected to I/R under control and 
high glucose conditions. Isolated rat hearts were perfused under high glucose conditions vs. 
controls and subjected to ischemia and reperfusion ± lactacystin treatment during reperfusion. 
Western blot analysis of ARC peptide levels is shown with β–actin as loading control. Values are 
expressed as mean ± SEM (n=8). **p<0.01, ***p<0.001 vs. respective controls. 
 
3.9 Lactacystin blunts inflammation in hearts exposed to ischemia and 
reperfusion under high glucose conditions 
The effects of proteasome inhibition on NFkβ activation were studied by analyzing Ikβα, 
NFkβ and IL-6 peptide levels. Here the data demonstrate that IkBα levels were lower with 
lactacystin treatment under control (p<0.01) and high glucose perfusion conditions 
(p<0.001) (Figure 3.19A). Likewise, higher NFkβ and IL-6 peptide levels usually found 
under high glucose conditions and lactacystin treatment blunted this (Figure 3.19B 
p<0.001 and 3.19C p<0.001). 
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Figure 3.19 Anti-inflammatory effects of lactacystin in hearts subjected to I/R under control 
and high glucose conditions. Isolated rat hearts were perfused under high glucose conditions vs. 
controls and subjected to ischemia and reperfusion ± lactacystin treatment during reperfusion. 
Western blot analysis for A) Ikβα; B) NFkβ and C) IL-6 peptide levels is shown with β–actin as 
loading control. Values are expressed as mean ± SEM (n=8). *p<0.05, **p<0.01, ***p<0.001 vs. 
respective controls. 
 
 
0.0
0.5
1.0
1.5
2.0
2.5
** ***
0 5 0 5 M Lactacystin
Control Hyperglycemia
I 
B
/ 
-a
c
ti
n
 (
A
U
)
0.0
0.5
1.0
1.5
2.0
0 5 0 5 M Lactacystin
*
*
***
Control Hyperglycemia
T
n
f-

/ 
-a
c
ti
n
 (
A
U
)
0
1
2
3
4
0 5 0 5 M Lactacystin
**
**
***
Control Hyperglycemia
IL
-6
/ 
-a
c
ti
n
 (
A
U
)
A B 
C 
0 5 0 5 
β -actin (45 kDa) 
IL-6 (22 kDa) 
0 5 0 5 0 5 0 5 
β -actin (45 kDa) β -actin (45 kDa) 
Ikβ (36 kDa) 
Tnf-α (17 kDa) 
Stellenbosch University  https://scholar.sun.ac.za
73 
 
 
3.10 Autophagy upregulated in lactacystin-treated hearts subjected to 
ischemia and reperfusion 
 
Due to the interplay between the UPS and autophagy we also investigated the effects of 
PI treatment on the autophagic system under high glucose perfusion conditions. These 
data show that the LC3 ratio and p62 (both markers of autophagy), were augmented under 
high glucose conditions (Figure 3.20). Lactacystin treatment increased the LC3 ratio 
(Figure 3.20A) under control (p<0.05) and high glucose conditions (p<0.001), while it 
decreased p62 levels (Figure 3.20B) under control (p<0.05) and high glucose conditions 
(p<0.001).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 Lactacystin increases autophagy in hearts subjected to I/R under control and 
high glucose conditions. Isolated rat hearts were perfused under high glucose conditions vs. 
controls and subjected to I/R  ± lactacystin treatment during reperfusion. Western blot analysis for 
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A) LC3I/LC3II ratio and B) P62 peptide levels is shown with β–actin as loading control. Values 
are expressed as mean ± SEM (n=8). *p<0.05, **p<0.01, ***p<0.001 vs. respective controls. 
3.11 Reduction in eNOS activation due to lactacystin under high glucose 
conditions 
 
We also assessed whether eNOS peptide levels could be correlated with our coronary 
flow results (perfusion data). Here eNOS levels were lowered by lactacystin treatment 
under control (p<0.01) and high glucose perfusion conditions (p<0.001) (Figure 3.21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.21 Lactacystin blunts eNOS in hearts subjected to I/R under control and high 
glucose conditions. Isolated rat hearts were perfused under high glucose conditions vs. controls 
and subjected to I/R ± lactacystin treatment during reperfusion. Western blot analysis eNOS 
peptide levels are shown with β–actin as loading control. Values are expressed as mean ± SEM 
(n=8). **p<0.01, ***p<0.001 vs. respective controls. 
 
 
 
 
 
3.12 Lactacystin blunts GR2K under high glucose conditions 
To gain additional insight into our functional data we evaluated GR2K peptide levels as it 
is linked with increased arrhythmias after an ischemic insult. These data revealed that 
GR2K levels were increased with lactacystin treatment under control (p<0.05) and high 
glucose condition (p<0.001) (Figure 3.18).  
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Figure 3.22 Lactacystin blunts GR2K in hearts subjected to I/R under control and high 
glucose conditions. Isolated rat hearts were perfused under high glucose conditions vs. controls 
and subjected to ischemia and reperfusion ± lactacystin treatment during reperfusion. Western 
blot analysis GR2K peptide levels are shown with β–actin as loading control. Values are 
expressed as mean ± SEM (n=8). *p<0.05, ***p<0.001 vs. respective controls. 
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Chapter 4: Discussion 
4.1 Introduction  
The dramatic surge in diabetes during the past few decades constitutes a major threat to 
human health in developed and developing nations (Wild S et al., 2004; Bradshaw D et al., 
2007). CVD frequently seen in diabetic patients, and here chronic hyperglycemia presents as 
a significant risk factor for acute myocardial infarction (AMI) (Cai L et al., 2002). Moreover, 
stress-induced, acute hyperglycemia in non-diabetic individuals with AMI is associated with 
increased in-hospital deaths (Capes SE et al., 2003). Thus, acute and hyperglycemia are able 
to trigger biochemical and electrophysiological perturbations which contributes to contractile 
dysfunction .Acute hyperglycemia (AHG) co-presenting with myocardial infarctions is 
associated with poor prognosis. Although AHG induces oxidative stress that may dysregulate 
the ubiquitin-proteasome system (UPS), it is unclear whether increased/decreased UPS is 
detrimental with ischemia-reperfusion under such conditions.  As our earlier studies 
implicated the UPS as a mediator of cardiac damage we therefor explored our hypothesis by 
employing ex vivo rat heart perfusion models (global and regional ischemia), Western blot 
analysis and various biochemical assays. The central discovery of this study is that PI 
treatment elicits cardio-protection in rat hearts by reducing hyperglycemia-induced 
oxidative stress, apoptosis, inflammation and proteasomal activity following I/R. 
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4.2 Cardio-protection using PIs after ischemia-reperfusion under 
simulated hyperglycemic conditions 
We initially examined our hypothesis by exposing isolated rat hearts to I/R and found a 
noticeable decline in contractile function under high glucose perfusion settings (simulated 
acute hyperglycemia). On the contrary, PI treatment with either MG-132 or lactacystin 
resulted in a prominent increase in functional recovery and shows that it elicits cardio-
protection under both normal and high glucose perfused rat hearts. The protective effect 
under baseline condition can be accounted by the fact that I/R per se can also lead to 
inflammation and other forms of oxidative stress which causes modification of lipids, 
proteins, and DNA (Ames et al., 1993, Evans J.L et al., 2002, Toth A et al., 2006). 
Furthermore, NO bioavailability is reduced with I/R along with alteration in cell signaling 
pathways due to increased oxidative stress, resulting in the activation of NFκβ and 
cardiomyocyte death. (Palombella et al., 1944).  However, PI administration at baseline 
may inhibit this sequence of events by increasing GSH levels and decreasing 
inflammation at baseline.  
Cardiac muscle contains 70% of 20s trypsin-like activity. Several studies  found that loss 
of the 20S trypsin-like activity linked with oxidative modification (4-
hydroxynonenalyation) of numerous proteasome subunits results in an increase in 
oxidized and ubiquitinated proteins and cardiomyocyte death (Powell et al., 2006, Powell 
SR et al., 2005, Xichun Yu and David C. Kem, 2010). However, our PIs did not result 
in the inhibition of trypsin-like proteasome activity and thus it may (in part) contribute to 
the cardio-protection observed. Infarct size data from both PIs further validated these, 
while MG-132 post-ischemic-treated hearts also showed improved coronary flow and 
reduced end diastolic pressure. However, in this study it is unclear which heart cells are 
targeted by such treatment but the endothelial cells are likely to be primary targets for 
example, the inhibition of the UPS triggers significant effects on endothelial cells, i.e. 
higher eNOS expression and activity, that can lead to improved endothelial function 
(Stangl V., Lorenz, M et al., 2004). This may therefore lead to increased oxygen supply 
to the myocardium resulting in improved post ischemic function (Kassiotis C et al., 
2008). Therefore further studies on especially the endothelium are needed to test whether 
this is the case in our experimental model. 
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When comparing the effects of the two PIs, MG-132 proved to be more effective than 
lactacystin. Various reasons can account for this, e.g. an artificial peptide substrate like 
lactacystin that can be cleaved by the proteasome particle might over-emphasize the role 
of the UPS resulting in it being less efficient (Liu Z et al., 2000). Secondly, the dosage of 
PIs plays a major role in its efficacy and therefore a lower dose of lactacystin may result 
in an improved recovery (Gurusamy N et al., 2008, Shirley RB et al., 2005). In 
addition, MG132 can protect cardiomyocytes from injury through induction of Hsp72 as 
well as Hsp32 and/ or activation of p38 MAP kinase (Lϋss H et al., 2002). MG-132 also 
has other properties and mechanisms that may exert additional effects on the systems 
such as calpain and cathepsins (Kisselev AF and Goldberg AL., 2001). Together these 
data suggest that MG-132 is likely to exert non-UPS effects that may also result in cardio-
protection. However, our findings strongly support a role for UPS inhibition as a novel 
cardio-protection agent.   
To gain a better understanding of the core mechanisms whereby PIs result in cardio-
protection, we evaluated whether it exhibits anti-oxidant and/or anti-apoptotic properties 
in our experimental systems. It is well established that myocardial ischemia-reperfusion is 
associated with increased ROS resulting in apoptotic and necrotic cell death (Buja LM 
and Entman ML., 1998, Murriel CL., 2004, Nabel EG., 2003). Moreover, glucose-
mediated toxicity results in oxidative stress due to an imbalance in terms of production of 
free radicals and intracellular antioxidant defenses (Kohner EM et al., 1998, Baynes 
JW., 1991). For this study we found that NAC improved functional recovery under high 
glucose conditions. In support, PARP was significantly raised together with decreased 
SOD activity and a reduced GSH levels under baseline. 
 The ROS generated in our model may stem from numerous sources in the heart, 
including the mitochondrial ETC, glucose auto-oxidation and uncoupled nitric oxide 
synthase (ucNOS) (Chen Q et al., 2003, Brownlee M., 2001). Other sources may include 
the NADPH oxidases as shown before by us (Joseph D et al., 2014). Such oxidative 
stress can lead to particular ubiquitin genes being upregulated to assist to clear damaged 
proteins (Sun L et al., 2002, Liu Z et al., 2000, Price SR et al., 1996). Thus PI-induced 
upregulation of cardiac SOD-1 may be a key mechanism to detoxify ROS in our model 
and may also reverse downstream effects. We are unclear regarding the transcriptional 
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modulators driving this system. However, the basic leucine zipper transcription factor, 
nuclear factor erythroid 2 related factor 2 (Nrf2), is strong candidate (Holtzclaw WD et 
al., 2004, Kobayashi A et al., 2004, Kwak MK et al., 2004). Nrf2 activates the 
expression of genes responsible for cytoprotection such as NAD (P) H dehydrogenase 
[quinone] 1 (NQO1) and glutathione S-transferase (GST) via an antioxidant/electrophile 
responsive gene promote element (ARE/EpRE) (Kobayashi M and Yamamoto M., 
2005, McMahon M et al., 2003, Motohashi H and Yamamoto M., 2004). Kelch ECH 
associating protein 1 (Keap1) acts as a stress sensor that suppresses Nrf2 activity and 
accelerates Nrf2 degradation by the UPS, thereby preventing Nrf2-individual 
transcription of target genes (Itoh K et al., 2003, McMahon M et al., 2003). UPS 
inhibition thus leads to Nrf2 accumulating in the nucleus and resulting in the activation of 
target genes. We propose it is likely the route whereby PIs may act as anti-oxidants with 
I/R under acute hyperglycemic conditions. However, further studies are needed to 
confirm this. 
The improved functional effects in our experimental model with PI treatment can also be 
attributed to its anti-apoptotic effects. This is likely to be a downstream effect, subsequent 
to elevated oxidative stress. Hyperglycemia leads to surplus free-radical generation and 
oxidative stress such as superoxide and NO which favors the production of peroxynitrite 
(ONOO¯) (Brownlee M., 2001). Peroxynitrite can in turn activate caspases such as 
caspase-3, essential for apoptosis (Virag L et al., 1998, Zhuang S et al., 2002). Here 
oxidative stress-induced apoptosis is initiated via Bax-mediated mitochondrial 
permeability and cytochrome c release resulting in the formation of an apoptosome with 
subsequent caspase-3 activation (Vincent AM et al., 2005). Moreover, high glucose 
levels attenuate the phosphorylation of Bad, which is associated with increased Bax/Bcl-2 
levels and cytochrome c release (Verzola D et al., 2002, Fernandez M et al., 2004). Our 
data are in agreement, i.e. various cell death markers were elevated with ischemia-
reperfusion under high glucose conditions. We also propose that p53 - a pro-apoptotic 
transcript regulated by MDM2 (which in turn is degraded by the UPS) - may play a role 
in this instance. MDM2 functions as an E3 ubiquitin ligase that can regulate p53 
degradation by the UPS. However, if the UPS is attenuated, this will result in greater 
intracellular p53 levels and enhanced anti-apoptotic effects (Toth et al., 2006). By 
contrast the ARC antagonizes: a) extrinsic-mediated apoptosis by non-homotypic death-
fold interaction with Fas (CD95/Apo-1) and FADD (Fas-associated death domain protein) 
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and b) intrinsic pathways of apoptosis via interactions between ARC and the C-terminal 
regulatory domain of Bax (Bcl-2-associated X protein) thereby preventing apoptotic 
stimuli (Wang M et al., 2005, Nam YJ et al., 2004, Gustafsson AB et al., 2004). This 
was reflected in our data where PI treatment triggered an attenuation of cell death markers 
together with increased anti-apoptotic markers (Figures 3.17 and 3.18). 
4.3 PI blunts inflammation in hearts exposed to ischemia-reperfusion 
under high glucose conditions 
Disproportionately elevated UPS activation can lead to the activation of harmful signaling 
pathways, e.g. NFκβ (Marfella R et al., 2009). The most significant association between 
the UPS and inflammation is linked to NFκβ. While, NFκβ is actively inhibited when 
bound to IκB, the latter’s degradation via the UPS can lead to its activation. The UPS can 
also control inflammatory pathways by regulation of macrophage function (Qureshi N et 
al., 2005). Various studies have linked pro-inflammatory cytokines, like TNF-α, IL-1β 
and IL-6, to the pathophysiology of heart disease (Sriramula S et al., 2008, Kang YM et 
al., 2008). Moreover, increased NF-κβ p50 sub-unit gene expression and NF-κβ p65 sub-
unit activity were found to be elevated under hyperglycemic conditions (Marfella R et 
al., 2009, Qureshi N et al., 2005).  In agreement, our data revealed that Ibuprofen 
improved heart recovery after I/R under high glucose conditions, together with a lower 
inflammatory response. In support, others found that blockade of NF-κβ in obese db/db 
mice shields the heart against oxidative stress by restoring mitochondrial integrity and 
improving cardiac function (Schreck R et al., 1992, Schreck R et al., 1991, Mariappan 
N et al., 2007, Mariappan N et al., 2009,). Furthermore, PI inhibition of inflammation 
resulted in enhanced cardiac function in response to ischemia-reperfusion (Evans J.L et 
al., 2002, Toth A et al., 2006). This was supported by another study where PS-519, a 
synthetic analog of lactacystin, which is a highly selective and potent proteasome 
inhibitor, resulted in a decrease of NF-kβ activation, attenuated the size of myocardial 
infarction, reduced reperfusion injury, and preserved regional myocardial function with 
ischemia and reperfusion (Pye J et al., 2003). Moreover, a decrease in p65 and TNF-α 
expression preserved Ikβ expression as PS-519 inhibited the NF-kβ inflammatory 
pathway activation (Figure 1.9) (Pye J et al., 2003). We do however, take into 
consideration that this data might be different when compared to other models such as in-
vivo. Nonetheless, together these findings show that glucose-mediated inflammation plays 
a detrimental role with ischemia and reperfusion. Though by, blunting the UPS we are 
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able to attenuate pro-inflammatory responses and this is linked with cardio-protection 
under such conditions. 
 
Figure 1.9. A schematic presentation of the activation of the NF-kβ Zolk et al., 2006. 
 
4.4 Other mechanisms involved in proteasome inhibition-mediated 
cardio-protection 
Normally with the inhibition of the UPS an increase in Ub proteins would be expected 
(Baracos VE et al., 1995, Powell SR., 2006, Pye J et al., 2003, Kastle M and Grune 
T., 2001). However, our findings showed the exact opposite where a decrease was 
observed. Enhanced autophagy was similarly detected in mouse hearts and isolated 
cardiomyocytes exposed to simulated I/R (Matsui Y et al., 2007, Valentim L et al., 
2006) and the functional role of autophagy in these conditions was examined. Matsui et 
al. revealed that reduced autophagy enhanced myocardial injury in acute myocardial 
ischemia (Matsui Y et al., 2007). Another study found that an autophagic marker in pig 
hearts with repetitive myocardial ischemia was prevalent in areas of sub-endocardium 
where apoptosis was lacking (Yan L et al., 2005). Therefore autophagy may contribute to 
the survival of cardiomyocytes in response to both acute and chronic MI. However, in our 
study we are unclear why this may be the case but recent research reveals an association 
of K63-linked poly-ubiquitin chains to the autophagy pathway (Kirkin V et al., 2006). 
Here adaptor molecules such as p62/SQSTM1 (referred to as p62 in this thesis) and 
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NBR1 enables the binding, by K63-linked damaged proteins, to both ubiquitin and 
autophagy machinery thereby linking the two pathways together (Bjorkoy G et al., 
2005). P62 can bind poly-ubiquitinated substrates through its ubiquitin-associated domain 
and directly binds to LC3 by the LC3 interacting region motif (Pankiv S et al., 2007) or 
via its PB1 domain and interacts with the proteasome by an UBL domain (Seibenhener 
ML et al., 2004). Thus the activation of autophagy in our system may help alleviate 
proteolytic stress (Kuusisto E et al., 2001) and could potentially explain our results. 
Taken collectively, p62 plays a crucial role in the formation of ubiquitin-positive 
inclusions, degradation of Ubproteins under stress, and is a perfect candidate for a 
messenger between the UPS and autophagy. However, further studies are required to 
confirm this. 
Another mechanism involved in PI-induced cardio-protection maybe via the (GR2K. 
Various studies reported a robust reduction in GR2K levels with CVD leading to 
ventricular tachyarrhythmias and sudden cardiac death (SCD) within minutes or hours 
following an acute myocardial infarction (Opitz CF et al., 1995, Patterson E et al., 
1991, Patterson E et al., 1991, Yu X et al., 2005). However, UPS inhibition leads to 
GR2K preservation (Figure 3.18) and would be expected to result in less/reduced 
occurrence of ventricular tachyarrhythmias and SCD. However, no SCD occurred in our 
treatment groups compared to controls, therefore it remains unclear whether this situation 
applies in our model or not. Further investigations are required to evaluate this effect in 
this and/or amended models. 
4.5 Conclusion 
This study examined the damaging effects of hyperglycemia in the setting of ischemia 
and reperfusion. Numerous deductions can be drawn from our work. We saw that 
hyperglycemia led to a poor cardiac function. UPS activity was increased in our model 
and can be attributed to the cardiac dysfunction. Our data revealed that oxidative stress, 
apoptosis and inflammation was increased under hyperglycemic conditions.  
Another important objective was to identify novel therapeutic agents that are able to blunt 
the harmful effects of hyperglycemia in the context of ischemia and reperfusion.  Our 
findings demonstrate that MG-132 and lactayctin can be used to treat acute 
hyperglycemia-induced cardiac contractile dysfunction. The PI’s were found to decrease 
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oxidative stress as well as apoptosis and limiting inflammation. These data are 
encouraging since it may ultimately result in novel therapeutic interventions to treat 
stress-induced acute hyperglycemia and diabetic patients with associated CVD 
complications such as MI.  
4.6 Future directions  
 
4.6.1 Limitations of the study 
The present study has certain limitations that need to be taken into account. The drug doses to 
prove anti-inflammatory and anti-oxidant activity of the PIs were based on non-rodent 
models (Yew et al., 2005; Meiners S et al., 2002; Use of NSAID for Relief of Pain in 
Rodents and Rabbits” Lab Animal 26: p. 241-255; Peng Y et al., 2011). Evaluations of 
the PIs under non-ischemic conditions are required to assess the effects of the PIs on normal 
cardiac tissue. Furthermore, even though ROS was linked by measuring SOD1/2 and GSH 
anti-oxidant levels, we acknowledge that other ROS regulators/mediators may also be 
implicated in the damaging effects of hyperglycemia and also impacting on the UPS, 
therefore other assesments would be useful such as ORCA, superoxide levels or GSH/GSSG 
ratio. Additionally, stronger evidence is also needed to link the cross-talk between the UPS 
and autophagy by assessing ubiquitin markers such as K48 as well as Nrf2 expression levels 
and/or its activation. These experiments will further strengthen our existing data. 
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Appendix 2 
Krebs-Henseleit stock solutions 
1. NaCl (279g/ 2L) 
2. NaHCO3 (83.6g/ 2L) 
3. KCl (17.6g) + K H2PO4 (8.1 g) in 2 L 
4. MgSO4. 7H2O (7.4g) + NaSO4 (4.2g) in 1L 
5. CaCl2.2H2O (18 g) in 1L 
To make up the 5 L working Krebs-Henseleit buffer mix 250ml of 1 and 2; add 100ml of 3 
and 4 then add glucose and finally # 5. Filter and p.H to 6.7 with HCl or NaOH. To make up 
11 mM glucose add 9.9 g and increase twice or thrice for 22 mM and 33 mM buffer 
solutions, respectively. 
Appendix 3 
Preparation of the triphenyl-tetrazolium chloride (TTC) solution 
Make up a high pH phosphate buffer by dissolving 14.2 mg of Na2HPO4 in a liter of distilled 
water and a low pH phosphate buffer by dissolving 12 mg of NaH2PO4 in a liter of distilled 
water. Mix in a ratio of 8 parts of the high pH buffer to 2 for the low pH buffer. pH to 7.4. 
For every heart use 5 ml of the mixed phosphate buffers and weigh 10 mg of the TTC salt for 
every 1 ml of the solution. Incubate the cut heart slices at 37 °C for 20 min shaking at least 
once. 
Appendix 4 
Determination of infarct size and area at risk using Image J software 
Select the heart slices using the third tool for polygon selections in the tools bar and pressing 
down on the Shift key of the keyboard. Determine the total area by clicking the Edit tab then 
select clear outside, thereafter click the Analyze tab and select Measure. A table with the first 
set of results shows and for infarct size use the area values. Thereafter click on the Image tab, 
select Split channels. Here 3 windows will open i.e. green, red, and blue channels. Close the 
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blue channel, use values from the green channel will be used for calculating infarct size and 
from the red channel area at risk. Here, it is advisable to do the analysis with a picture of the 
heart alongside. In either of the green or red channel, click on the Image tab, select Adjust 
threshold and using the eighth tool select the respective highlighted area in the heart slices 
corresponding to the infarct size and area at risk, respectively. Thereafter click on the 
Analyze tab and select measure. At the end three readings should appear for total area, infarct 
size and area at risk. For the calculations substract the second and third readings from the 
total area to obtain infarct size and area at risk values, respectively. These are calculated for 
both sides of the heart slices and expressed as infarct size/area at risk. 
 
Appendix 5 
Modified RIPA Buffer: 
A 100 ml modified RIPA buffer contains: 
 50 mM Tris-HCl (790 mg of Tris in 75 ml distilled water and 900 mg of NaCl and pH 
made 7.4 using HCl) 
 10 ml of 10% NP-40 [final concentration 1%] 
 2.5 ml of 10% sodium deoxycholate [final concentration 0.25%] 
 1 ml of 100 mM EDTA pH 7.4 [final concentration 1 mM] 
 Protease inhibitors 
 500 μL of 200 mM phenylmethylsulfonyl fluoride (PMSF) [final concentration 1 
mM] 
 100 μL of Leupeptin (1 mg/ml water) [final concentration 1 μg/ml] 
 80 μL of SBT1 (5 mg/ml water) [final concentration 4 μg/ml] 
 100 μL of Benzamidine (1 M) [final concentration 1 mM] 
 Protein phosphatase inhibitors 
 500 μL of 200 mM activated sodium orthovanadate (Na2VO3) [final concentration 1 
mM] 
 500 μL of 200 mM NaF [final concentration 1mM] 
- 1 ml Triton X-100 
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This buffer is then made up to a final volume of 100 ml with distilled water and stored at -
20°C. 
Appendix 6 
Bradford protein quantification method: 
Bradford reagent 
 500 mg of Coomassie Brilliant Blue G in 250 ml of 95% ethanol 
 500 ml of phosphoric acid 
This is made up to 1 litre using distilled water, filtered and stored at 4°C. 
Working solution: 
The Bradford stock is diluted in 1:5 ratio using distilled water, filtered and used for protein 
quantification. 
Bradford method: 
BSA (1 mg/ml) is diluted in a 1:4 ratio using distilled water. A protein standard with varying 
protein concentrations is prepared as follows: 
BSA (μL) 
 
BSA concentration (μg) Volume of distilled water 
(μL) 
0 Blank 100 
10 2 80 
20 4 60 
40 6 40 
60 8 20 
80 12 10 
100 14 0 
5 Unknown protein sample 95 
 
To all these protein and BSA standards, 900 μL of Bradford working solution is added and 
vortexed gently. Samples were allowed to stand for ~ 5 minutes. The absorbancies of each 
Stellenbosch University  https://scholar.sun.ac.za
116 
 
sample was read using a spectrophotometer at 595 nm. (If the protein absorbancies fall 
outside the protein standard, the proteins must be diluted with RIPA buffer and reading taken 
again). The absorbancies were then plotted to construct a linear plot for the standards. 
Thereafter the amounts of protein in unknown samples were quantified in relation to the 
linear standard plot. 
Sample preparation (tissue lysates) Western blotting- SDS-PAGE: 
Set heating block temperature to 99 °C and keep samples on ice, and allow thawing. A stock 
solution of sample buffer containing 850 μL sample buffer and 150 μL mercaptoethanol is 
prepared. A volume of sample buffer equivalent to 1/3 final volume of the sample must be 
added (under the fume hood). The appropriate amounts of proteins are added to each tube 
calculated previously. Tiny holes are punched on the lids of microfuge tubes (containing the 
prepared sample) and placed in boiling water for about 5 minutes. The tubes are then briefly 
spun in a table top centrifuge. Samples can now be used for Western blot analysis or 
alternatively be stored at -80°C for later use. 
SDS = denature proteins, constant anionic charge-to-mass ration 
Glycerol = give sample a higher density than buffer to “sink” to the bottom of the well 
Mercaptoethanol = reduce disulfide bonds present in protein sample 
SDS-PAGE -Western blotting 
Insert commercially available 10-well precast Mini-PROTEAN® TGX Stain-Free™ 
polyalcrylamide gels stand and place them in the U-shaped adaptor cassette with the small 
plates facing inward. Retrieve prepared samples from the -80 C freezer and allow it to thaw 
on ice. Once thawed, vortex each sample briefly before denaturing on the heating block for 5 
minutes. Place the U-shaped adaptor into the loading system and push the latches closed, 
away from your body. Carefully pour running buffer into the middle compartment between 
the gel plates, allowing the buffer to flow over the wells. Add 10 μl of pre-stained weight 
marker (peqGOLD, PEQLAB Biotechnologie GMBH, Germany) into the first well on the left 
of each gel for orientation and electrophoretic determination of molecular weights of specific 
bands. Hereafter add 50 μg of protein samples into each well in the desired order using a 
micropipette and clean loading tips for every sample. Place the system into the outer running 
chamber; add the running buffer until ~1cm below the wells. Place the green lid with 
Stellenbosch University  https://scholar.sun.ac.za
117 
 
electrical leads onto the cell system, making sure to attach the electrodes correctly i.e. red to 
red and black to black. Run gels were run for 60 minutes at 100 V (constant) and 400 mA 
(Mini Protean System, Bio-Rad, USA) for 10 minutes then the voltage was increased to 200 
V with the same current for 60 minutes. 
Electrotransfer of proteins: 
Cut two chromatography filter papers and one 0.2 micron polyvinylidine fluoride (PVDF) 
membranes (Immunibilon, Millipore, USA). Soak filter papers in transfer buffer and for the 
membrane first soak in methanol for 15 seconds, thereafter wash with distilled water before 
soaking in transfer buffer. Place on filter paper onto the semi-dry apparatus (Bio-Rad, USA) 
and carefully place the PVDF membranes on top. Roll with a wet tube to remove any 
bubbles. Hereafter place gels onto membranes making sure to get rid of any bubbles with a 
wet tube. To complete the sandwich place filter paper on top of the gel, close the system and 
run at limit 0.5 A and 15 V for ~ 1 h. 
Detection of proteins (Western blots):  
Probing the membrane In order to prevent non-specific binding membranes was blocked in 5 
% (weight/volume) fat-free milk in 0.1 % Tris Buffered Saline-Tween 20 (TBS-T) for 2 
hours at room temperature. Membranes were then incubated with the respective primary 
antibody diluted in 5 % (w/v) fat-free milk in 0.1 % TBS-T (1: 1000), overnight at 4 °C. 
Hereafter on the following day, membranes were washed a further three times in TBS-T (3x5 
minutes) before being incubated in the secondary anti-mouse/rabbit/sheep/goat HRP 
monoclonal antibody (1:4000) for 1 hour at room temperature with gentle agitation. 
For detection of the antibodies, membranes were treated with 2 ml ECL LumiGLO Reserve 
TM chemiluminescent substrate kit (KPL, Inc., USA) as per manufacturer’s instructions. It 
was then dried on tissue paper, placed between transparencies and was then developed in a 
dark room where bands were exposed to autoradiography film (Hyperfilm, Amersham 
Biosciences, UK). The film was then developed by placing it in developing solution until 
bands appeared followed by 15 seconds in a fixative. This film was then visualised and 
quantified by densitometry using the UNSCAN-IT© densitometry software (Silk Scientific 
Corporation, Utah, USA). All bands were expressed as optical density readings relative to a 
control present on the same blot. 
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Appendix 7 
Buffers used during Western blotting 
10 x TBS (STOCK – store in fridge) 
 48.4 g Tris 
 160 g NaCl 
Dissolve in 500 ml distilled water, set pH to 7.6 with concentrated HCl and then make up to 2 
L. 
10X running buffer (STOCK – store in fridge) 
 Tris base 60.6 g 
 Glycine 288 g 
 10 % SDS 20 g 
Dissolve in 2 liter distilled water. 
Transfer buffer (ready to use) 
In a 1L bottle add : 
 100 ml Biorad 10X transfer buffer 
 200 ml methanol 
 700 ml dH2O 
 
Stellenbosch University  https://scholar.sun.ac.za
